JP4921162B2 - 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 - Google Patents
熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 Download PDFInfo
- Publication number
- JP4921162B2 JP4921162B2 JP2006502254A JP2006502254A JP4921162B2 JP 4921162 B2 JP4921162 B2 JP 4921162B2 JP 2006502254 A JP2006502254 A JP 2006502254A JP 2006502254 A JP2006502254 A JP 2006502254A JP 4921162 B2 JP4921162 B2 JP 4921162B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- isoxazole
- carboxylic acid
- dihydroxy
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002545 isoxazoles Chemical class 0.000 title abstract description 7
- 239000003112 inhibitor Substances 0.000 title abstract description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 title description 12
- 102000002812 Heat-Shock Proteins Human genes 0.000 title description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 190
- -1 isopropylaminocarbonyl group Chemical group 0.000 claims description 146
- 150000001875 compounds Chemical class 0.000 claims description 82
- 239000000725 suspension Substances 0.000 claims description 51
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- GVNFOZYVKKSCJY-UHFFFAOYSA-N chembl254458 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 GVNFOZYVKKSCJY-UHFFFAOYSA-N 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- WLYWTGDTMWWNNG-UHFFFAOYSA-N chembl399583 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C(C=C1)=CC=C1CN1CCOCC1 WLYWTGDTMWWNNG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 230000003381 solubilizing effect Effects 0.000 claims description 4
- APGOABVITLQCKW-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 APGOABVITLQCKW-UHFFFAOYSA-N 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- RNLVKRYMKWCANV-UHFFFAOYSA-N chembl400187 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 RNLVKRYMKWCANV-UHFFFAOYSA-N 0.000 claims description 3
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- LURPCKMCPZKVLG-UHFFFAOYSA-N 3-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound CCNC(=O)C=1ON=C(C=2C(=CC(O)=C(Cl)C=2)O)C=1C(C=C1)=CC=C1CN1CCOCC1 LURPCKMCPZKVLG-UHFFFAOYSA-N 0.000 claims description 2
- OVJLXNJAQKKVCO-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-N-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 OVJLXNJAQKKVCO-UHFFFAOYSA-N 0.000 claims description 2
- RQRUBPKAYFDPFF-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 RQRUBPKAYFDPFF-UHFFFAOYSA-N 0.000 claims description 2
- PCXWAYHFMKPLQV-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(ethylaminomethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(CNCC)=CC=C1C1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)ON=C1C(=O)NCC PCXWAYHFMKPLQV-UHFFFAOYSA-N 0.000 claims description 2
- KIPRUYSELCZZTP-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-[(2-methoxyethylamino)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CNCCOC)C=C1 KIPRUYSELCZZTP-UHFFFAOYSA-N 0.000 claims description 2
- LRQGHEGCJYDULB-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 LRQGHEGCJYDULB-UHFFFAOYSA-N 0.000 claims description 2
- FWXKZIWZSRANCX-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-[(propan-2-ylamino)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CNC(C)C)C=C1 FWXKZIWZSRANCX-UHFFFAOYSA-N 0.000 claims description 2
- KZJAWYUJSFALRK-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-4-[4-(piperidin-1-ylmethyl)phenyl]-N-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCCCC1 KZJAWYUJSFALRK-UHFFFAOYSA-N 0.000 claims description 2
- WDORNDZICKCYOH-UHFFFAOYSA-N 5-(5-tert-butyl-2,4-dihydroxyphenyl)-4-[4-(diethylaminomethyl)phenyl]-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C1=CC=C(CN(CC)CC)C=C1 WDORNDZICKCYOH-UHFFFAOYSA-N 0.000 claims description 2
- ZTLWCZRCEYWCOR-UHFFFAOYSA-N 5-(5-tert-butyl-2,4-dihydroxyphenyl)-N-ethyl-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 ZTLWCZRCEYWCOR-UHFFFAOYSA-N 0.000 claims description 2
- IAFDYDGLYZZMSJ-UHFFFAOYSA-N 5-[2,4-dihydroxy-5-(2-methylpropyl)phenyl]-N-ethyl-4-[4-(piperidin-1-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCCCC1 IAFDYDGLYZZMSJ-UHFFFAOYSA-N 0.000 claims description 2
- NAIOWGXKMUYTEJ-UHFFFAOYSA-N N-ethyl-5-(5-ethyl-2,4-dihydroxyphenyl)-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 NAIOWGXKMUYTEJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- KVALWNOGXNZJNM-UHFFFAOYSA-N chembl252165 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 KVALWNOGXNZJNM-UHFFFAOYSA-N 0.000 claims description 2
- FQKHRMZPORXQSR-UHFFFAOYSA-N chembl252370 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCCCC1 FQKHRMZPORXQSR-UHFFFAOYSA-N 0.000 claims description 2
- COBVQNNJVURGON-UHFFFAOYSA-N chembl253185 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C(C=C1)=CC=C1CN1CCCCC1 COBVQNNJVURGON-UHFFFAOYSA-N 0.000 claims description 2
- AEZSTVRHWTURDU-UHFFFAOYSA-N chembl253399 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 AEZSTVRHWTURDU-UHFFFAOYSA-N 0.000 claims description 2
- LALDVGOZMSLLOR-UHFFFAOYSA-N chembl253837 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 LALDVGOZMSLLOR-UHFFFAOYSA-N 0.000 claims description 2
- RUXXRSDEOCYOTM-UHFFFAOYSA-N chembl427716 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 RUXXRSDEOCYOTM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract description 67
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract description 60
- 230000000694 effects Effects 0.000 abstract description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 245
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 166
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 142
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 116
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- 238000000034 method Methods 0.000 description 104
- 239000000203 mixture Substances 0.000 description 100
- 235000019439 ethyl acetate Nutrition 0.000 description 95
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 91
- 239000007787 solid Substances 0.000 description 89
- 230000008569 process Effects 0.000 description 87
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- 238000005481 NMR spectroscopy Methods 0.000 description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 56
- 230000014759 maintenance of location Effects 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 50
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 49
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- 229920006395 saturated elastomer Polymers 0.000 description 39
- 239000003921 oil Substances 0.000 description 34
- 235000019198 oils Nutrition 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 27
- 235000019441 ethanol Nutrition 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 201000006417 multiple sclerosis Diseases 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000012299 nitrogen atmosphere Substances 0.000 description 24
- 238000010992 reflux Methods 0.000 description 24
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 238000003556 assay Methods 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 20
- 239000012043 crude product Substances 0.000 description 20
- 238000001914 filtration Methods 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 229960000583 acetic acid Drugs 0.000 description 19
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 19
- 239000012267 brine Substances 0.000 description 19
- 238000002875 fluorescence polarization Methods 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- 108010006519 Molecular Chaperones Proteins 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 238000012746 preparative thin layer chromatography Methods 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 102000005431 Molecular Chaperones Human genes 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229940107698 malachite green Drugs 0.000 description 11
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 9
- 108091006112 ATPases Proteins 0.000 description 9
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- QTQAWLPCGQOSGP-KSRBKZBZSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-KSRBKZBZSA-N 0.000 description 9
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 9
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 9
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 8
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 241000400611 Eucalyptus deanei Species 0.000 description 7
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 125000002837 carbocyclic group Chemical group 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000001665 trituration Methods 0.000 description 7
- SULYEHHGGXARJS-UHFFFAOYSA-N 2',4'-dihydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1O SULYEHHGGXARJS-UHFFFAOYSA-N 0.000 description 6
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 5
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 5
- 229930192524 radicicol Natural products 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 4
- FYUABHFDUHJWOZ-UHFFFAOYSA-N 1-[2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC=C1OCC1=CC=CC=C1 FYUABHFDUHJWOZ-UHFFFAOYSA-N 0.000 description 4
- QVFIWTNWKHFVEH-UHFFFAOYSA-N 4-benzylbenzene-1,3-diol Chemical compound OC1=CC(O)=CC=C1CC1=CC=CC=C1 QVFIWTNWKHFVEH-UHFFFAOYSA-N 0.000 description 4
- FAQQNPUMRKZXOQ-UHFFFAOYSA-N 4-bromo-5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1Br FAQQNPUMRKZXOQ-UHFFFAOYSA-N 0.000 description 4
- JXPCDMPJCKNLBY-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-(4-methoxyphenyl)isoxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(OC)C=C1 JXPCDMPJCKNLBY-UHFFFAOYSA-N 0.000 description 4
- LEVXOZABOPNCSR-UHFFFAOYSA-N 7-hydroxy-3-(4-methoxyphenyl)-2-methylchromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(C)OC2=CC(O)=CC=C2C1=O LEVXOZABOPNCSR-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 0 CN=CC=CC(c1c(-c(cc(*)c(O)c2)c2O)[o]nc1*)=CC=C* Chemical compound CN=CC=CC(c1c(-c(cc(*)c(O)c2)c2O)[o]nc1*)=CC=C* 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- JQMGJSXGRAGDCL-UHFFFAOYSA-N chembl252328 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)OC)=C1C(C=C1)=CC=C1CN1CCOCC1 JQMGJSXGRAGDCL-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 229960001755 resorcinol Drugs 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- KEUCDMZJTGJAQX-UHFFFAOYSA-N 1-[5-chloro-2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC(Cl)=C1OCC1=CC=CC=C1 KEUCDMZJTGJAQX-UHFFFAOYSA-N 0.000 description 3
- IJYAWQDRWLYGOA-UHFFFAOYSA-N 1-[5-tert-butyl-2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC(C(C)(C)C)=C1OCC1=CC=CC=C1 IJYAWQDRWLYGOA-UHFFFAOYSA-N 0.000 description 3
- DVACAEYJLSVVCC-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]benzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(O)=CC=2)O)ON=C1C DVACAEYJLSVVCC-UHFFFAOYSA-N 0.000 description 3
- UVPKKGOKMWXSLZ-UHFFFAOYSA-N 4-bromo-n-ethyl-5-[5-(2-phenylethyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(CCC=3C=CC=CC=3)C=2)OCC=2C=CC=CC=2)=C1Br UVPKKGOKMWXSLZ-UHFFFAOYSA-N 0.000 description 3
- ZZMGXKYVZXMJRP-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-iodo-3-methyl-1,2-oxazole Chemical compound CC1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1I ZZMGXKYVZXMJRP-UHFFFAOYSA-N 0.000 description 3
- GDAMMRJAXVIWCB-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-(4-formylphenyl)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C1=CC=C(C=O)C=C1 GDAMMRJAXVIWCB-UHFFFAOYSA-N 0.000 description 3
- ZQAFABVGJPDBNB-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 ZQAFABVGJPDBNB-UHFFFAOYSA-N 0.000 description 3
- FLUACTQPZIYQCV-UHFFFAOYSA-N 7-hydroxy-3-(4-methoxyphenyl)-2-methyl-6-phenylchromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(C)OC2=CC(O)=C(C=3C=CC=CC=3)C=C2C1=O FLUACTQPZIYQCV-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102100039328 Endoplasmin Human genes 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- PWYURLHJDYKRHM-UHFFFAOYSA-N chembl438695 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OC)=C(CC)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 PWYURLHJDYKRHM-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 108010017007 glucose-regulated proteins Proteins 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- QYUJMZDXFKTDAQ-UHFFFAOYSA-N n-ethyl-5-(5-ethyl-2,4-dimethoxyphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OC)=C(CC)C=2)OC)=C1C(C=C1)=CC=C1CN1CCOCC1 QYUJMZDXFKTDAQ-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001315 phosphanylidene group Chemical group [H]P=* 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 150000003217 pyrazoles Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- XHBZOAYMBBUURD-UHFFFAOYSA-N 1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(O)C=C1O XHBZOAYMBBUURD-UHFFFAOYSA-N 0.000 description 2
- CVJQCEUAIVQCDK-UHFFFAOYSA-N 1-(5-chloro-2,4-dihydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(Cl)=C(O)C=C1O CVJQCEUAIVQCDK-UHFFFAOYSA-N 0.000 description 2
- QDDBVZBZUZGBKH-UHFFFAOYSA-N 1-(5-tert-butyl-2,4-dihydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(C(C)(C)C)=C(O)C=C1O QDDBVZBZUZGBKH-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 2
- RLXQJELUJMDJFL-UHFFFAOYSA-N 1-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(C)C)=CC(C(C)=O)=C1OCC1=CC=CC=C1 RLXQJELUJMDJFL-UHFFFAOYSA-N 0.000 description 2
- GNFGGGZOFBRFBZ-UHFFFAOYSA-N 1-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(CC(C)C)=CC(C(C)=O)=C1OCC1=CC=CC=C1 GNFGGGZOFBRFBZ-UHFFFAOYSA-N 0.000 description 2
- NFLKIWJCSWXDPU-UHFFFAOYSA-N 1-[[3-[5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-3-methyl-1,2-oxazol-4-yl]phenyl]methyl]piperidine-4-carboxamide Chemical compound CC1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C(C=1)=CC=CC=1CN1CCC(C(N)=O)CC1 NFLKIWJCSWXDPU-UHFFFAOYSA-N 0.000 description 2
- DCWPPXDQCNZIEI-UHFFFAOYSA-N 1-methyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine Chemical compound C1CN(C)CCN1C1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 DCWPPXDQCNZIEI-UHFFFAOYSA-N 0.000 description 2
- BMUQCXQKEZAKPW-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-1-prop-1-en-2-ylbenzene Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=C)C)=CC=C1OCC1=CC=CC=C1 BMUQCXQKEZAKPW-UHFFFAOYSA-N 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- PJSRTIQUYSSLSP-UHFFFAOYSA-N 3-[2,4-dihydroxy-5-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]phenyl]prop-2-enoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(O)=C(C=CC(O)=O)C=2)O)ON=C1C PJSRTIQUYSSLSP-UHFFFAOYSA-N 0.000 description 2
- OJQKGZGQMPHDFI-UHFFFAOYSA-N 3-[4-(4-bromophenyl)-1,2-oxazol-5-yl]-5-chloro-2,6-dihydroxybenzaldehyde Chemical compound OC1=C(C=O)C(O)=C(Cl)C=C1C1=C(C=2C=CC(Br)=CC=2)C=NO1 OJQKGZGQMPHDFI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DQKRTTZVIMZNLE-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]-2,6-bis[(4-methylpiperazin-1-yl)methyl]benzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=C(CN3CCN(C)CC3)C(O)=C(CN3CCN(C)CC3)C=2)O)ON=C1C DQKRTTZVIMZNLE-UHFFFAOYSA-N 0.000 description 2
- UYEHHIWIPTZRGA-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]-6-(2-phenylethenyl)benzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(O)=C(C=CC=3C=CC=CC=3)C=2)O)ON=C1C UYEHHIWIPTZRGA-UHFFFAOYSA-N 0.000 description 2
- UFMWEUKJIITMHK-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]-6-phenylbenzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(O)=C(C=2)C=2C=CC=CC=2)O)ON=C1C UFMWEUKJIITMHK-UHFFFAOYSA-N 0.000 description 2
- JBGLNZUZSASUHD-UHFFFAOYSA-N 4-bromo-6-[4-(4-methoxyphenyl)-5-methyl-1,2-oxazol-3-yl]benzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C)ON=C1C1=CC(Br)=C(O)C=C1O JBGLNZUZSASUHD-UHFFFAOYSA-N 0.000 description 2
- NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 2
- BJIAFNGRIJWAOE-UHFFFAOYSA-N 5-(3-chloro-4-hydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C=C(Cl)C(O)=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 BJIAFNGRIJWAOE-UHFFFAOYSA-N 0.000 description 2
- CIZMYXGWCJRVRR-UHFFFAOYSA-N 5-(5-chloro-2-hydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 CIZMYXGWCJRVRR-UHFFFAOYSA-N 0.000 description 2
- GXBPNDXCBOAEDY-UHFFFAOYSA-N 5-[5-bromo-2,4-bis(phenylmethoxy)phenyl]-4-(4-methoxyphenyl)-3-methyl-1,2-oxazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(OCC=3C=CC=CC=3)=C(Br)C=2)OCC=2C=CC=CC=2)ON=C1C GXBPNDXCBOAEDY-UHFFFAOYSA-N 0.000 description 2
- MYEXHIZUUXNARE-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 MYEXHIZUUXNARE-UHFFFAOYSA-N 0.000 description 2
- ZGQGLAKLCOKHKM-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-(4-methoxyphenyl)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C1=CC=C(OC)C=C1 ZGQGLAKLCOKHKM-UHFFFAOYSA-N 0.000 description 2
- CXEWLBZEOVMZRA-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-[3-(4-methylpiperazin-1-yl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C(C=1)=CC=CC=1N1CCN(C)CC1 CXEWLBZEOVMZRA-UHFFFAOYSA-N 0.000 description 2
- HPCFGMJARCBPRP-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-iodo-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1I HPCFGMJARCBPRP-UHFFFAOYSA-N 0.000 description 2
- WZYLAUMKNKGRFO-UHFFFAOYSA-N 5-[5-tert-butyl-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(C(C)(C)C)=C1OCC1=CC=CC=C1 WZYLAUMKNKGRFO-UHFFFAOYSA-N 0.000 description 2
- OWQIJHTZPIMEBM-UHFFFAOYSA-N 5-[5-tert-butyl-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C=2)C(C)(C)C)OCC=2C=CC=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 OWQIJHTZPIMEBM-UHFFFAOYSA-N 0.000 description 2
- MLBOARCKWYIPFI-UHFFFAOYSA-N 5-[5-tert-butyl-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-iodo-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C=2)C(C)(C)C)OCC=2C=CC=CC=2)=C1I MLBOARCKWYIPFI-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- UOCGHKPNBDOLDX-UHFFFAOYSA-N C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C(=O)OCC)=CC(Cl)=C1OCC1=CC=CC=C1 Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C(=O)OCC)=CC(Cl)=C1OCC1=CC=CC=C1 UOCGHKPNBDOLDX-UHFFFAOYSA-N 0.000 description 2
- 241001480079 Corymbia calophylla Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 241001417528 Nematistiidae Species 0.000 description 2
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000000944 Soxhlet extraction Methods 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- HUZNRXFJHYNUMV-UHFFFAOYSA-N [4-(aminomethyl)phenyl]boronic acid;hydron;chloride Chemical compound Cl.NCC1=CC=C(B(O)O)C=C1 HUZNRXFJHYNUMV-UHFFFAOYSA-N 0.000 description 2
- QLVOEFKDWVOJSL-UHFFFAOYSA-N [5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-(4-fluorophenyl)-1,2-oxazol-3-yl]methanamine Chemical compound NCC1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C1=CC=C(F)C=C1 QLVOEFKDWVOJSL-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000012866 crystallographic experiment Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 2
- KQIUKKGKUOXUJI-UHFFFAOYSA-N ethyl 5-(2-benzoyloxy-5-chlorophenyl)-4-bromo-1,2-oxazole-3-carboxylate Chemical compound CCOC(=O)C1=NOC(C=2C(=CC=C(Cl)C=2)OC(=O)C=2C=CC=CC=2)=C1Br KQIUKKGKUOXUJI-UHFFFAOYSA-N 0.000 description 2
- JWLDSZFGMHPMOO-UHFFFAOYSA-N ethyl 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(C(C)C)=C1OCC1=CC=CC=C1 JWLDSZFGMHPMOO-UHFFFAOYSA-N 0.000 description 2
- XXBYWIRHKPLEHO-UHFFFAOYSA-N ethyl 5-[5-tert-butyl-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(C(C)(C)C)=C1OCC1=CC=CC=C1 XXBYWIRHKPLEHO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- DQDUWZNYLDDIPB-UHFFFAOYSA-N methyl 2,4-dihydroxy-5-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC(C2=C(C(C)=NO2)C=2C=CC(OC)=CC=2)=C1O DQDUWZNYLDDIPB-UHFFFAOYSA-N 0.000 description 2
- NPYHYVUJHAGVOP-UHFFFAOYSA-N methyl 2-benzoyloxy-5-chlorobenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1OC(=O)C1=CC=CC=C1 NPYHYVUJHAGVOP-UHFFFAOYSA-N 0.000 description 2
- ZADABWXBKIZIGE-UHFFFAOYSA-N methyl 5-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]-2,4-bis(phenylmethoxy)benzoate Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(=O)OC)=CC=1C=1ON=C(C)C=1C1=CC=C(OC)C=C1 ZADABWXBKIZIGE-UHFFFAOYSA-N 0.000 description 2
- VVJYGMYBEBSFGA-UHFFFAOYSA-N n-ethyl-4-(4-formylphenyl)-5-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(CC(C)C)C=2)OCC=2C=CC=CC=2)=C1C1=CC=C(C=O)C=C1 VVJYGMYBEBSFGA-UHFFFAOYSA-N 0.000 description 2
- DEWDPXUQZKHXAS-UHFFFAOYSA-N n-ethyl-5-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(CC(C)C)C=2)OCC=2C=CC=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 DEWDPXUQZKHXAS-UHFFFAOYSA-N 0.000 description 2
- TYITVCDJTSOTAR-UHFFFAOYSA-N n-ethyl-5-[5-(2-phenylethenyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(C=CC=2C=CC=CC=2)=C1OCC1=CC=CC=C1 TYITVCDJTSOTAR-UHFFFAOYSA-N 0.000 description 2
- DBNZOHJEKRWFMM-UHFFFAOYSA-N n-ethyl-5-[5-(2-phenylethyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(CCC=2C=CC=CC=2)=C1OCC1=CC=CC=C1 DBNZOHJEKRWFMM-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 2
- 229960002950 novobiocin Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 2
- OTYPIDNRISCWQY-UHFFFAOYSA-L palladium(2+);tris(2-methylphenyl)phosphane;dichloride Chemical compound Cl[Pd]Cl.CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C.CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C OTYPIDNRISCWQY-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000008684 selective degradation Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- XSKBGEUBVLSATM-UHFFFAOYSA-N tert-butyl 3-[5-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]-2,4-bis(phenylmethoxy)phenyl]prop-2-enoate Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(OCC=3C=CC=CC=3)=C(C=CC(=O)OC(C)(C)C)C=2)OCC=2C=CC=CC=2)ON=C1C XSKBGEUBVLSATM-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ILFIRBGRMCGNOO-UHFFFAOYSA-N 1,1-bis($l^{1}-oxidanyl)ethene Chemical group [O]C([O])=C ILFIRBGRMCGNOO-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- YFIAXNACMLJXRX-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)ethanone Chemical compound CC(C)C1=CC(C(C)=O)=C(O)C=C1O YFIAXNACMLJXRX-UHFFFAOYSA-N 0.000 description 1
- XMZKXYBXQCAUHQ-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-methylpropan-1-one Chemical compound CC(C)C(=O)C1=CC=C(O)C=C1O XMZKXYBXQCAUHQ-UHFFFAOYSA-N 0.000 description 1
- HJRZEXYEOXVFGH-UHFFFAOYSA-N 1-(3-bromophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CC(Br)=C1 HJRZEXYEOXVFGH-UHFFFAOYSA-N 0.000 description 1
- WCOODAWUEIXTFL-UHFFFAOYSA-N 1-(4-bromophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(Br)C=C1 WCOODAWUEIXTFL-UHFFFAOYSA-N 0.000 description 1
- PJHPFAFEJNBIDC-UHFFFAOYSA-N 1-(4-bromophenyl)piperazine Chemical compound C1=CC(Br)=CC=C1N1CCNCC1 PJHPFAFEJNBIDC-UHFFFAOYSA-N 0.000 description 1
- UXNPREOAQGSYKG-UHFFFAOYSA-N 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(4-fluorophenyl)ethanone Chemical compound C1=C(O)C(CC)=CC(C(=O)CC=2C=CC(F)=CC=2)=C1O UXNPREOAQGSYKG-UHFFFAOYSA-N 0.000 description 1
- GWQCWCPHAWVRGR-UHFFFAOYSA-N 1-[2,4-dihydroxy-5-(2-methylpropyl)phenyl]ethanone Chemical compound CC(C)CC1=CC(C(C)=O)=C(O)C=C1O GWQCWCPHAWVRGR-UHFFFAOYSA-N 0.000 description 1
- IQCKVPICYMYKBD-UHFFFAOYSA-N 1-[5-bromo-2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC(Br)=C1OCC1=CC=CC=C1 IQCKVPICYMYKBD-UHFFFAOYSA-N 0.000 description 1
- YLWDFQJAXLVYEQ-UHFFFAOYSA-N 1-[[3-[5-(5-chloro-2,4-dihydroxyphenyl)-3-methyl-1,2-oxazol-4-yl]phenyl]methyl]piperidine-4-carboxamide Chemical compound CC1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=1)=CC=CC=1CN1CCC(C(N)=O)CC1 YLWDFQJAXLVYEQ-UHFFFAOYSA-N 0.000 description 1
- SUVCZZADQDCIEQ-UHFFFAOYSA-N 1-isocyanato-2-methoxybenzene Chemical compound COC1=CC=CC=C1N=C=O SUVCZZADQDCIEQ-UHFFFAOYSA-N 0.000 description 1
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FGSUVLQGYZEZPR-UHFFFAOYSA-N 3-(4-bromophenyl)-6-chloro-7-hydroxy-4-oxochromene-8-carbaldehyde Chemical compound O=CC=1C(O)=C(Cl)C=C(C2=O)C=1OC=C2C1=CC=C(Br)C=C1 FGSUVLQGYZEZPR-UHFFFAOYSA-N 0.000 description 1
- ZWYXWSDCLKYHLR-UHFFFAOYSA-N 3-(4-methoxyphenyl)-2-methyl-2H-chromen-7-ol Chemical compound OC1=CC=C2C=C(C(OC2=C1)C)C1=CC=C(C=C1)OC ZWYXWSDCLKYHLR-UHFFFAOYSA-N 0.000 description 1
- OKKSBTOKHROSHT-UHFFFAOYSA-N 3-[5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-3-methyl-1,2-oxazol-4-yl]benzaldehyde Chemical compound CC1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C1=CC=CC(C=O)=C1 OKKSBTOKHROSHT-UHFFFAOYSA-N 0.000 description 1
- RYIIFLBQTLTZRQ-UHFFFAOYSA-N 3-[5-bromo-2,4-bis(phenylmethoxy)phenyl]-4-(4-methoxyphenyl)-5-methyl-1,2-oxazole Chemical compound C1=CC(OC)=CC=C1C1=C(C)ON=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Br)=C1OCC1=CC=CC=C1 RYIIFLBQTLTZRQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GQMPHUXGZCDVGQ-UHFFFAOYSA-N 3-bromo-1,2-oxazole Chemical compound BrC=1C=CON=1 GQMPHUXGZCDVGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- IFVWLEMMYISKHW-UHFFFAOYSA-N 4-(2-methylpropyl)benzene-1,3-diol Chemical compound CC(C)CC1=CC=C(O)C=C1O IFVWLEMMYISKHW-UHFFFAOYSA-N 0.000 description 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical group NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- NKVDDTQRFOFFBM-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]-6-(2-phenylethyl)benzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(O)=C(CCC=3C=CC=CC=3)C=2)O)ON=C1C NKVDDTQRFOFFBM-UHFFFAOYSA-N 0.000 description 1
- XWAKANMSVGJPQD-UHFFFAOYSA-N 4-[4-(diethylaminomethyl)phenyl]-5-[2,4-dihydroxy-5-(2-methylphenyl)phenyl]-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C(=CC=CC=2)C)O)=C1C1=CC=C(CN(CC)CC)C=C1 XWAKANMSVGJPQD-UHFFFAOYSA-N 0.000 description 1
- NSVZNIOGSFQMSQ-UHFFFAOYSA-N 4-[4-(diethylaminomethyl)phenyl]-N-ethyl-5-[5-(4-fluorophenyl)-2,4-dihydroxyphenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C=CC(F)=CC=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 NSVZNIOGSFQMSQ-UHFFFAOYSA-N 0.000 description 1
- WNCGSWNZVHEESS-UHFFFAOYSA-N 4-[4-[(cyclohexylamino)methyl]phenyl]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CNC1CCCCC1 WNCGSWNZVHEESS-UHFFFAOYSA-N 0.000 description 1
- INSHMVKUWUOWCX-UHFFFAOYSA-N 4-[4-[(tert-butylamino)methyl]phenyl]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CNC(C)(C)C)C=C1 INSHMVKUWUOWCX-UHFFFAOYSA-N 0.000 description 1
- JOIXYIWXEYXHHG-UHFFFAOYSA-N 4-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1CN1CCOCC1 JOIXYIWXEYXHHG-UHFFFAOYSA-N 0.000 description 1
- NVAUTMYITXYGDI-UHFFFAOYSA-N 4-benzyl-6-[4-(4-methoxyphenyl)-3-methyl-1,2-oxazol-5-yl]benzene-1,3-diol Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C(=CC(O)=C(CC=3C=CC=CC=3)C=2)O)ON=C1C NVAUTMYITXYGDI-UHFFFAOYSA-N 0.000 description 1
- BXCVIKYDYWWBJY-UHFFFAOYSA-N 4-bromo-5-(5-chloro-2-phenylmethoxyphenyl)-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC=C(Cl)C=2)OCC=2C=CC=CC=2)=C1Br BXCVIKYDYWWBJY-UHFFFAOYSA-N 0.000 description 1
- YSYLGOABRJHWLS-UHFFFAOYSA-N 4-chloro-6-[3-methyl-4-[3-(morpholin-4-ylmethyl)phenyl]-1,2-oxazol-5-yl]benzene-1,3-diol Chemical compound CC1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=1)=CC=CC=1CN1CCOCC1 YSYLGOABRJHWLS-UHFFFAOYSA-N 0.000 description 1
- JQVAPEJNIZULEK-UHFFFAOYSA-N 4-chlorobenzene-1,3-diol Chemical compound OC1=CC=C(Cl)C(O)=C1 JQVAPEJNIZULEK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SVRIZBMCPTWVQV-UHFFFAOYSA-N 4-iodo-5-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound CC(C)CC1=CC(=C(C=C1OCC2=CC=CC=C2)OCC3=CC=CC=C3)C4=C(C(=NO4)C(=O)O)I SVRIZBMCPTWVQV-UHFFFAOYSA-N 0.000 description 1
- LNFVQIGQENWZQN-UHFFFAOYSA-N 4-propan-2-ylbenzene-1,3-diol Chemical compound CC(C)C1=CC=C(O)C=C1O LNFVQIGQENWZQN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VJZBSHKIQOPPRU-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(C(C(O)=O)=NO2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O VJZBSHKIQOPPRU-UHFFFAOYSA-N 0.000 description 1
- YPDVIDMKANWNSH-UHFFFAOYSA-N 5-(3-chloro-4-phenylmethoxyphenyl)-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C=C(Cl)C(OCC=3C=CC=CC=3)=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 YPDVIDMKANWNSH-UHFFFAOYSA-N 0.000 description 1
- MZLFTCWJVHVMMQ-UHFFFAOYSA-N 5-(5-chloro-2-phenylmethoxyphenyl)-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 MZLFTCWJVHVMMQ-UHFFFAOYSA-N 0.000 description 1
- HMPPNHPKLRFAOO-UHFFFAOYSA-N 5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-fluorophenyl)-N-hydroxy-1,2-oxazole-3-carboxamide Chemical compound C1=C(OC)C(CC)=CC(C2=C(C(C(=O)NO)=NO2)C=2C=CC(F)=CC=2)=C1O HMPPNHPKLRFAOO-UHFFFAOYSA-N 0.000 description 1
- SOJLZBYLPPKTDG-UHFFFAOYSA-N 5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound CCC1=CC(=C(C=C1OC)O)C2=C(C(=NO2)C(=O)O)C3=CC=C(C=C3)CN4CCOCC4 SOJLZBYLPPKTDG-UHFFFAOYSA-N 0.000 description 1
- COSRPZYHRYMHMJ-UHFFFAOYSA-N 5-(5-tert-butyl-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide formic acid Chemical compound OC=O.CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(c(O)cc1O)C(C)(C)C COSRPZYHRYMHMJ-UHFFFAOYSA-N 0.000 description 1
- BEZNKTGLEYAPEN-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(C(C)C)=C1OCC1=CC=CC=C1 BEZNKTGLEYAPEN-UHFFFAOYSA-N 0.000 description 1
- XPXSLNCYHCALKY-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 XPXSLNCYHCALKY-UHFFFAOYSA-N 0.000 description 1
- IMGRXNUBIXWPRF-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-4-iodo-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1I IMGRXNUBIXWPRF-UHFFFAOYSA-N 0.000 description 1
- MRMPJRZAHVWVRN-UHFFFAOYSA-N 5-[2,4-dihydroxy-5-(2-methylpropyl)phenyl]-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound OC1=C(C=C(C(=C1)O)CC(C)C)C1=C(C(=NO1)C(=O)O)C1=CC=C(C=C1)CN1CCOCC1 MRMPJRZAHVWVRN-UHFFFAOYSA-N 0.000 description 1
- IAIFNNSAOSERAK-UHFFFAOYSA-N 5-[2,4-dihydroxy-5-(2-phenylethyl)phenyl]-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide hydrochloride Chemical compound Cl.CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CCC=3C=CC=CC=3)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 IAIFNNSAOSERAK-UHFFFAOYSA-N 0.000 description 1
- RCOLJCMOCJTIHT-UHFFFAOYSA-N 5-[5-(2-phenylethenyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C(=C1)OCC1=CC=CC=C1)C=CC1=CC=CC=C1)C1=CC(=NO1)C(=O)O RCOLJCMOCJTIHT-UHFFFAOYSA-N 0.000 description 1
- WOWKDRDXOOHSNT-UHFFFAOYSA-N 5-[5-bromo-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Br)=C1OCC1=CC=CC=C1 WOWKDRDXOOHSNT-UHFFFAOYSA-N 0.000 description 1
- NGLBCMMOEXJLNI-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 NGLBCMMOEXJLNI-UHFFFAOYSA-N 0.000 description 1
- OCOLKBULVPHOCO-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-(3-chlorophenyl)-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C1=CC=CC(Cl)=C1 OCOLKBULVPHOCO-UHFFFAOYSA-N 0.000 description 1
- LQSJDSUCPCNMGE-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-(4-fluorophenyl)-1,2-oxazole-3-carboxamide N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-fluorophenyl)-1,2-oxazol-3-yl]methyl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C(=C1)OCC1=CC=CC=C1)Cl)C1=C(C(=NO1)C(=O)N)C1=CC=C(C=C1)F.ClC=1C(=CC(=C(C1)C1=C(C(=NO1)CNC(C)=O)C1=CC=C(C=C1)F)O)O LQSJDSUCPCNMGE-UHFFFAOYSA-N 0.000 description 1
- QJBHOFOBOCSGIY-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-iodo-1,2-oxazole-3-carboxamide Chemical compound NC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1I QJBHOFOBOCSGIY-UHFFFAOYSA-N 0.000 description 1
- XGTDIVXCRKZUPB-UHFFFAOYSA-N 5-[5-tert-butyl-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-(4-formylphenyl)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C=2)C(C)(C)C)OCC=2C=CC=CC=2)=C1C1=CC=C(C=O)C=C1 XGTDIVXCRKZUPB-UHFFFAOYSA-N 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100035634 B-cell linker protein Human genes 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ROJQRZHPVSWKBT-UHFFFAOYSA-N C(C)(=O)O.ClC=1C(=CC(=C(C1)C(C)=O)O)O Chemical compound C(C)(=O)O.ClC=1C(=CC(=C(C1)C(C)=O)O)O ROJQRZHPVSWKBT-UHFFFAOYSA-N 0.000 description 1
- FYFIIKDHDSZVDW-UHFFFAOYSA-N C(C)N.C(C)NC(=O)C1=NOC(=C1)C1=C(C=C(C(=C1)Cl)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound C(C)N.C(C)NC(=O)C1=NOC(=C1)C1=C(C=C(C(=C1)Cl)OCC1=CC=CC=C1)OCC1=CC=CC=C1 FYFIIKDHDSZVDW-UHFFFAOYSA-N 0.000 description 1
- LAMKNQRQSUOLNK-UHFFFAOYSA-N C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C(=O)OCC)=CC(C(C)C)=C1OCC1=CC=CC=C1 Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C(=O)OCC)=CC(C(C)C)=C1OCC1=CC=CC=C1 LAMKNQRQSUOLNK-UHFFFAOYSA-N 0.000 description 1
- PDRQWICBTJDLOV-UHFFFAOYSA-N C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C)=CC(Cl)=C1OCC1=CC=CC=C1 Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C)=CC(Cl)=C1OCC1=CC=CC=C1 PDRQWICBTJDLOV-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- HNKFJAFYUCOWLD-UHFFFAOYSA-N C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1ON=C(C(O)=O)C=1I Chemical compound C=1C=CC=CC=1COC=1C=C(OCC=2C=CC=CC=2)C(C(C)C)=CC=1C=1ON=C(C(O)=O)C=1I HNKFJAFYUCOWLD-UHFFFAOYSA-N 0.000 description 1
- YEYJXZIXHVWOBJ-VTBWFHPJSA-N CCOC(C1=NC1([C@@H](c(cc1)ccc1OC(c1ccccc1)=O)O)Br)=O Chemical compound CCOC(C1=NC1([C@@H](c(cc1)ccc1OC(c1ccccc1)=O)O)Br)=O YEYJXZIXHVWOBJ-VTBWFHPJSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- KPYNFTQDBSWCDH-UHFFFAOYSA-N Cc(cc(cc1)C(OC)=O)c1OC(c1ccccc1)=O Chemical compound Cc(cc(cc1)C(OC)=O)c1OC(c1ccccc1)=O KPYNFTQDBSWCDH-UHFFFAOYSA-N 0.000 description 1
- PREPFACMUANUTD-UHFFFAOYSA-N Cc1n[o]c(-c(cc(c(O)c2)Cl)c2O)c1C(CC1)=CC=C1OC Chemical compound Cc1n[o]c(-c(cc(c(O)c2)Cl)c2O)c1C(CC1)=CC=C1OC PREPFACMUANUTD-UHFFFAOYSA-N 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 1
- 101000763352 Homo sapiens Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- IBDRZKZXYYEVKU-UHFFFAOYSA-N N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-fluorophenyl)-1,2-oxazol-3-yl]methyl]acetamide Chemical compound CC(=O)NCC1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(F)C=C1 IBDRZKZXYYEVKU-UHFFFAOYSA-N 0.000 description 1
- OTLWQBIRGRIAIP-UHFFFAOYSA-N N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-fluorophenyl)-1,2-oxazol-3-yl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(F)C=C1 OTLWQBIRGRIAIP-UHFFFAOYSA-N 0.000 description 1
- JPGYKDKHPGWGHZ-UHFFFAOYSA-N N-ethyl-2H-1,3-oxazole-3-carboxamide Chemical compound C(C)NC(=O)N1COC=C1 JPGYKDKHPGWGHZ-UHFFFAOYSA-N 0.000 description 1
- KOEWQOUBZIGXIF-UHFFFAOYSA-N N-ethyl-5-[5-(2-fluorophenyl)-2,4-dihydroxyphenyl]-4-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C(=CC=CC=2)F)O)=C1C(C=C1)=CC=C1CN1CCCC1 KOEWQOUBZIGXIF-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UHMRMQFGKRRISH-UHFFFAOYSA-N [2-chloro-5-diethoxyphosphoryloxy-4-[3-(ethylcarbamoyl)-4-(4-methoxyphenyl)-1,2-oxazol-5-yl]phenyl] diethyl phosphate Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OP(=O)(OCC)OCC)=C(Cl)C=2)OP(=O)(OCC)OCC)=C1C1=CC=C(OC)C=C1 UHMRMQFGKRRISH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- PCCNIENXBRUYFK-UHFFFAOYSA-O azanium;cerium(4+);pentanitrate Chemical compound [NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PCCNIENXBRUYFK-UHFFFAOYSA-O 0.000 description 1
- HKVFISRIUUGTIB-UHFFFAOYSA-O azanium;cerium;nitrate Chemical compound [NH4+].[Ce].[O-][N+]([O-])=O HKVFISRIUUGTIB-UHFFFAOYSA-O 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QZAGRDWEPBNZOM-UHFFFAOYSA-N benzene-1,3-diol 1-(2,4-dihydroxyphenyl)-2-methylpropan-1-one Chemical compound C1(O)=CC(O)=CC=C1.OC1=C(C=CC(=C1)O)C(C(C)C)=O QZAGRDWEPBNZOM-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KTLFENNEPHBKJD-UHFFFAOYSA-K benzyl(trimethyl)azanium;tribromide Chemical compound [Br-].[Br-].[Br-].C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1 KTLFENNEPHBKJD-UHFFFAOYSA-K 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- NBORIEUQDSFVFQ-UHFFFAOYSA-N chembl253836 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CCC=3C=CC=CC=3)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NBORIEUQDSFVFQ-UHFFFAOYSA-N 0.000 description 1
- IFYJCWYDVYZPLI-UHFFFAOYSA-N chembl254248 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C=CC=CC=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 IFYJCWYDVYZPLI-UHFFFAOYSA-N 0.000 description 1
- VYTQJAUFGNWPHH-UHFFFAOYSA-N chembl400186 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=1)=CC=CC=1N1CCN(C)CC1 VYTQJAUFGNWPHH-UHFFFAOYSA-N 0.000 description 1
- YAYJACNPYWHUDS-UHFFFAOYSA-N chembl401370 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C=CC=CC=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 YAYJACNPYWHUDS-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NTBQNWBHIXNPRU-MSQVLRTGSA-L disodium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O NTBQNWBHIXNPRU-MSQVLRTGSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ZCUIIEYEIFBQGT-UHFFFAOYSA-N ethyl 3-(2-benzoyloxy-5-chlorobenzoyl)-3-bromoazirine-2-carboxylate Chemical compound CCOC(=O)C1=NC1(Br)C(=O)C1=CC(Cl)=CC=C1OC(=O)C1=CC=CC=C1 ZCUIIEYEIFBQGT-UHFFFAOYSA-N 0.000 description 1
- MWITVYBCJVLEHB-UHFFFAOYSA-N ethyl 3-(4-benzoyloxy-3-chlorobenzoyl)-3-bromoazirine-2-carboxylate Chemical compound CCOC(=O)C1=NC1(Br)C(=O)C(C=C1Cl)=CC=C1OC(=O)C1=CC=CC=C1 MWITVYBCJVLEHB-UHFFFAOYSA-N 0.000 description 1
- LOUSNZDBSOMHHM-UHFFFAOYSA-N ethyl 4-(5-ethyl-2,4-dihydroxyphenyl)-3-(4-fluorophenyl)-2,4-dioxobutanoate Chemical compound C=1C=C(F)C=CC=1C(C(=O)C(=O)OCC)C(=O)C1=CC(CC)=C(O)C=C1O LOUSNZDBSOMHHM-UHFFFAOYSA-N 0.000 description 1
- ZVVVOKJWRJQHQS-UHFFFAOYSA-N ethyl 4-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoate Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)CC(=O)C(=O)OCC)=CC(CC(C)C)=C1OCC1=CC=CC=C1 ZVVVOKJWRJQHQS-UHFFFAOYSA-N 0.000 description 1
- AEBJVUZYLOMSIM-UHFFFAOYSA-N ethyl 4-[5-bromo-2,4-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoate Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)CC(=O)C(=O)OCC)=CC(Br)=C1OCC1=CC=CC=C1 AEBJVUZYLOMSIM-UHFFFAOYSA-N 0.000 description 1
- UKIPXGHIRAYBJO-UHFFFAOYSA-N ethyl 5-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(CC(C)C)=C1OCC1=CC=CC=C1 UKIPXGHIRAYBJO-UHFFFAOYSA-N 0.000 description 1
- RUCWEGAOXNNRGK-UHFFFAOYSA-N ethyl 5-[5-bromo-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Br)=C1OCC1=CC=CC=C1 RUCWEGAOXNNRGK-UHFFFAOYSA-N 0.000 description 1
- QACSKDRRGBHPOF-UHFFFAOYSA-N ethyl 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 QACSKDRRGBHPOF-UHFFFAOYSA-N 0.000 description 1
- JVGSUVKIJMZEHU-UHFFFAOYSA-N ethyl 6-ethyl-3-(4-fluorophenyl)-7-hydroxy-4-oxochromene-2-carboxylate Chemical compound CCOC(=O)C=1OC2=CC(O)=C(CC)C=C2C(=O)C=1C1=CC=C(F)C=C1 JVGSUVKIJMZEHU-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- ZFDIRQKJPRINOQ-UHFFFAOYSA-N ethyl but-2-enoate Chemical compound CCOC(=O)C=CC ZFDIRQKJPRINOQ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- ZHOGHWVKKXUAPI-UHFFFAOYSA-N fluorooxy(phenyl)borinic acid Chemical compound FOB(O)C1=CC=CC=C1 ZHOGHWVKKXUAPI-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- HBEFVZMJESQFJR-UHFFFAOYSA-N isocyanatosulfanylbenzene Chemical compound O=C=NSC1=CC=CC=C1 HBEFVZMJESQFJR-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- MPNRZNQPOTYKHV-UHFFFAOYSA-N methyl 4-benzoyloxy-3-chlorobenzoate Chemical compound ClC1=CC(C(=O)OC)=CC=C1OC(=O)C1=CC=CC=C1 MPNRZNQPOTYKHV-UHFFFAOYSA-N 0.000 description 1
- KJWHRMZKJXOWFC-UHFFFAOYSA-N methyl 5-chloro-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1O KJWHRMZKJXOWFC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- BBMQDQPCOQKBFT-UHFFFAOYSA-N n-[[5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-(3-chlorophenyl)-1,2-oxazol-3-yl]methyl]ethanamine Chemical compound CCNCC1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1C1=CC=CC(Cl)=C1 BBMQDQPCOQKBFT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JZWQGHAERZIZGM-UHFFFAOYSA-N n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C=1C=CON=1 JZWQGHAERZIZGM-UHFFFAOYSA-N 0.000 description 1
- ANBUJMWOANLDDD-UHFFFAOYSA-N n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-5-[5-(2-phenylethyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(CCC=3C=CC=CC=3)C=2)OCC=2C=CC=CC=2)=C1C(C=C1)=CC=C1CN1CCOCC1 ANBUJMWOANLDDD-UHFFFAOYSA-N 0.000 description 1
- MKNAHEIBXIZFJG-UHFFFAOYSA-N n-ethyl-5-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(CC(C)C)=C1OCC1=CC=CC=C1 MKNAHEIBXIZFJG-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- ZVQXQPNJHRNGID-UHFFFAOYSA-N tetramethylsuccinonitrile Chemical compound N#CC(C)(C)C(C)(C)C#N ZVQXQPNJHRNGID-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZDEBAOFPRYZWLD-UHFFFAOYSA-N trifluoroborane;trimethyloxidanium Chemical compound C[O+](C)C.FB(F)F ZDEBAOFPRYZWLD-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Description
細胞が、熱ショック、アルコール、重金属および酸化的ストレスを含む多くの環境ストレスに曝されると、熱ショック蛋白質(HSPs)として一般に知られている多数のシャペロンが、細胞に蓄積する結果となる。HSPsの誘導は、初期ストレス傷害から細胞を保護し、再生を高め、そしてストレス耐性状態の維持を導く。しかしながら、ある種のHSPsは、正常な、ストレスのない状態のもとでは、重要な細胞蛋白質の成長への正しい折りたたみ、分解、局在および機能を調節することにより、主要な分子シャペロンの役割を果たすことも明らかとなっている。
HSP90は、全細胞蛋白質の約1〜2%を構成しており、通常は、他の多くの蛋白質の一つと結合して2量体として細胞中に存在している(例えば、Pratt、1997参照)。それは、細胞生存のために必須のものであり、二元的なシャペロン機能を表す(Youngら、2001)。それは、種々の環境ストレス、例えば熱ショックによって本来の立体構造が変化させられた後に多くの蛋白質と相互作用すること、適切な蛋白質の折りたたみを保証すること、および非特異的な凝集を防ぐことによって、細胞のストレス応答において重要な役割を果たしている(Smithら、1998)。さらに、最近の結果は、HSP90は、多分、突然変異蛋白質の不適当な折りたたみを修正することにより、突然変異の影響を緩和する役割を果たすことも示唆している(RutherfordおよびLindquist、1998)。
発見されたHSP90阻害剤の最初のクラスは、ベンゾキノン アンサマイシン クラスであり、それはハービマイシンAおよびゲルダナマイシンを含んでいる。それらにより、v-Src腫瘍形成遺伝子で形質転換された繊維芽細胞の悪性の遺伝表現型が逆転することが示され(Ueharaら、1985)、次いで、インビトロ(Schulteら、1998)そしてインビボの動物モデル(Supkoら、1995)の両方で、強力な抗腫瘍活性を有することが示された。
分子シャペロンHSP90が、腫瘍の遺伝表現型を誘導する際に極めて重要である多くのシグナル経路を調節することに関わっていること、およびある種の生物活性天然物が、HSP90への活性を経てそれらの効果を発揮することの発見により、現在、分子シャペロンHSP90が抗癌剤開発のための新規な標的として、評価されている(Neckersら、1999)。
本発明はHSP90阻害剤として、例えば癌細胞増殖の阻害のための置換イソオキサゾール化合物のクラスの使用に関する。本発明はそれ自体新規なイソオキサゾール化合物およびそれらを含む医薬組成物にも関する。
R1は、式(IA):
-Ar1-(Alk1)p-(Z)r-(Alk2)s-Q (IA)
(ここで、何れかの共存できる組合せで(in any compatible combination)、
Ar1は任意に置換していてもよいアリールまたはヘテロアリール基であり、
Alk1およびAlk2 は任意に置換していてもよい二価のC1〜C6アルキレンまたはC2〜C6アルケニレン基であり、
p、rおよびsは独立して0または1であり、
Qは水素または任意に置換していてもよい炭素環式もしくは複素環式基である)
の基であり、
(ii) カルボキサミド基;または
(iii) 非芳香族炭素環または複素環(ここで、環炭素および/または環窒素は式-(Alk1)p-(Z)r-(Alk2)s-Q (ここで、Q、Alk1、Alk2、Z、p、rおよびsは基(IA)に関して上記で定義したとおりである)の基により任意に置換されていてもよい);そして
の化合物またはそれらの塩、N−オキサイド、水和物もしくは溶媒和物、あるいはそれらのプロドラッグの使用が提供される。
用語「カルボキシ基」は式 -COOHの基をさし;
用語「カルボキシエステル基」は式 -COOR (ここで、Rはヒドロキシ化合物ROHに実際または概念的に由来する基である)をさし;そして
用語「カルボキサミド基」は式-CONRaRb (ここで、-NRaRbはアンモニアまたはアミンHNRaRbに実際または概念的に由来する第1級または2級(環式を含む)アミノ基である)をさす。
本発明のいくつかの化合物は、不斉炭素原子の存在により、一つ以上の実際のまたは潜在的なキラル中心を有する。いくつかの不斉炭素原子の存在は、各々のキラル中心でのRまたはS立体化学を有する、多くのジアステレオマーを生じさせる。本発明は、そのようなジアステレオマーおよびそれらの混合物の全てを含む。
もう一つの観点は、HSP90活性阻害に応答する疾患の治療のためのそのような化合物の使用を含む。
一般に、R1基に存在する基Ar1は、好ましくはイソオキサゾール環に対するフェニル環の結合に関して2位にヒドロキシ基がある任意の置換基の一つで任意に置換されていてもよいフェニルであることが目下のところ好ましい。言い換えれば、基R1は好ましくは式(IB):
を有する。
上記のタイプのR1基の具体例はこの中の実施例の化合物中に存在する。
R2がタイプ(i)、すなわち式(IA)の基である場合、例はフェニル、2-、3-もしくは4-ピリジル、2-もしくは3-フラニル、2-もしくは3-チエニルおよびチアゾリル(ここで、任意の置換基は「置換」の定義において上記のもののいずれか、例えばメトキシ、エトキシ、メチレンジオキシ、エチレンジオキシ、フルオロ、クロロ、ブロモおよびトリフルオロメチルを含む)を含む。例えばR2はメトキシもしくはエトキシのようなC1〜C6 アルコキシ、またはフルオロ、クロロ、ブロモ、ピペラジニル、N-メチルピペラジニルもしくはピペリジニルにより4位で置換されているフェニルであり得る。
nは0または1であり、
RBは水素またはC1〜C6アルキルまたはC2〜C6アルケニル基、例えばメチル、エチル、n-もしくはiso-プロピルまたはアリルであり、
RAはヒドロキシまたは任意に置換されていてもよい炭素環式、例えばヒドロキシおよび/またはクロロ-置換フェニルおよび3,4メチレンジオキシフェニル;あるいは複素環式、例えばピリジル、フリル、チエニル、N-ピペラジニル、またはN-モルホリニルであり、そのヘテロ環のいずれかは置換されることができるか、あるいは、
のカルボキサアミドを含む。
R3は、例えば水素、メチル、エチル、n-またはiso-プロピル、トリフルオロメチル、ヒドロキシエチル、メチルスルホンアミノメチル、またはR2のための上記のようなカルボキサミド基 -CONRB(Alk)nRAであり得る。カルボキサミド基が好ましく、特にエチルアミノカルボニルおよびイソプロピルアミノカルボニルが好ましい。
ならびにそれらの位置異性体式Bのもの、およびそれらの塩、溶媒和物および水和物、ならびにそれらのプロドラッグからなる。
R3は(エチルアミノカルボニル CH3CH2NHC(=O)-またはイソプロピルアミノカルボニル (CH3)2CHNHC(=O)-のような)カルボキサミド基を表し;R9は-CH2NR10R11または-NR10R11(ここで、置換アミノ基 -NR10R11は(モルホリニル、ピペリジニル、ピペラジニル、ピロリジニル、エチルアミノ、イソプロピルアミノ、ジエチルアミノ、シクロヘキシルアミノ、シクロペンチルアミノ、メトキシエチルアミノ、ピペリジン-4-イル、N-アセチルピペラジニル、N-メチルピペラジニル、メチルスルホニルアミノ、チオモルホリニル、チオモルホリニル-ジオキサイド、4-ヒドロキシエチルピペリジニルおよび4-ヒドロキシピペリジニル、のような)溶解補助基である)を表し;そしてR8は任意の置換基、(エチル、イソプロピル、ブロモまたはクロロのような)特に小さな親油性の基を表す)
ならびにそれらの位置異性体式Bのもの、およびそれらの塩、溶媒和物および水和物、ならびにそれらのプロドラッグからなる。
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-エチルアミノメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
4-(4-シクロヘキシルアミノメチル-フェニル)-5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
4-[4-(tert-ブチルアミノ-メチル)-フェニル]-5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-[4-[(2-メトキシ-エチルアミノ)-メチル]-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 イソプロピルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソブチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソブチル-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-(4-ジエチルアミノメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
3-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-5-カルボン酸 エチルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(4,6-ジヒドロキシ-2'-メチル-ビフェニル-3-イル)-イソオキサゾール-3-カルボン酸 エチルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(4'-フルオロ-4,6-ジヒドロキシ-ビフェニル-3-イル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2'-フルオロ-4,6-ジヒドロキシ-ビフェニル-3-イル)-4-(4-ピロリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(4,6-ジヒドロキシ-ビフェニル-3-イル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-フェネチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 イソプロピルアミド
5-(5-エチル-2,4-ジヒドロキシ-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-エチル-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-ジエチルアミノメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
のもの、ならびにそれらの塩、N-オキサイド、水和物および溶媒和物ならびにプロドラッグを含む。
の化合物との反応により製造できる。
の反応により、イソオキサゾール(V):
(i) HSP90活性阻害に有効な、上記で定義したような式(A)もしくは(B)の化合物、またはそれらの塩、水和物または溶媒和物の量を哺乳動物に投与することを含む方法であって、哺乳動物、特にヒトの該HSP90活性の阻害に応答する疾患または病態の治療方法;そして
(ii) ヒトまたは動物の医薬、特にHSP90活性の阻害に応答する疾患または病態の治療に使用するための、上記で定義したような式(A)もしくは(B)の化合物、またはそれらの塩、水和物または溶媒和物;
も含む。
特に、本発明は無菌の、生理学的に許容される担持体、例えば生理食塩水中のそのような化合物の溶液または懸濁液を含む
も提供する。
1-(2,4-ジヒドロキシ-フェニル)-2-(4-メトキシ-フェニル)-エタノン
LC保持時間2.39分間 [M+H]+ 259.2 (実施時間3.75分間)
N.M.R (DMSO-d6) 7.95(d J 8.9Hz ArH) 7.2(d J 8.7Hz 2ArH) 6.9(d J 8.7Hz 2ArH) 6.4(d J 9.9 ArH) 6.25(s ArH) 4.2(s 2CH2) 3.75(s 3OCH3)
7-ヒドロキシ-3-(4-メトキシ-フェニル)-2-メチル-クロメン-4-オン
LC保持時間2.26分間 [M+H]+ 283.2 (実施時間3.75分間)
N.M.R (DMSO-d6) 7.8(d J 8.7Hz ArH) 7.2(d J 8.8Hz 2ArH) 7.0(d J 8.8Hz 2ArH) 6.9(d J 8.7 ArH) 6.8(s ArH) 3.8(s 3OCH3) 2.2(s 3CH3)
4-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-ベンゼン-1,3-ジオール
LC保持時間2.20分間 [M+H]+ 298.2 (実施時間3.75分間)
N.M.R (DMSO-d6) 7.1(d J 8.8Hz 2ArH) 6.85(d J 8.6Hz ArH) 6.8(d J 8.8Hz 2ArH) 6.25(s ArH) 6.15(d J 8.6Hz ArH) 3.65(s 3OCH3) 2.15(s 3CH3)
4-ブロモ-6-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-ベンゼン-1,3-ジオール
LC保持時間2.38分間 [M+H]+ 378.2 (実施時間3.75分間)
N.M.R (アセトン-d6) 7.35(s ArH) 7.2(d J 8.8Hz 2ArH) 6.9(d J 8.8Hz 2ArH) 6.65(s ArH) 3.8(s 3OCH3) 2.25(s 3CH3)
5-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール
LC保持時間3.08分間 [M+H]+ 558.4 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.55(s ArH) 7.35-7.25(m 5ArH) 7.2(m 3ArH) 6.95(d J 8.8Hz 2ArH) 6.85(m 2ArH) 6.7(d J 8.8Hz 2ArH) 6.35(s ArH) 4.95(s 2CH2) 4.6(s 2CH2) 3.75(s 3OCH3) 2.25(s 3CH3)
5-(4,6-ビス-ベンジルオキシ-ビフェニル-3-イル)-4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール
LC保持時間3.08分間 [M+H]+ 554.4 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.4(m 2ArH) 7.35(s ArH) 7.3-7.1(m 11ArH) 6.95(d J 8.8Hz 2ArH) 6.9(m 2ArH) 6.7(d J 8.8Hz 2ArH) 6.45(s ArH) 4.9(s 2CH2) 4.7(s 2CH2) 3.75(s 3OCH3) 2.25(s 3CH3)
7-ヒドロキシ-3-(4-メトキシ-フェニル)-2-メチル-6-フェニル-クロメン-4-オン
LC保持時間2.58分間 [M+H]+ 359.2 (実施時間3.75分間)
N.M.R (DMSO-d6) 7.9(s ArH) 7.5-7.3(m 5ArH) 7.25(d J 8.8Hz 2ArH) 7.1 (s ArH) 7.05(d J 8.8Hz 2ArH) 3.85(s 3OCH3) 2.2(s 3CH3)
5-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-ビフェニル-2,4-ジオール
LC保持時間2.56分間 [M+H]+ 374.3 (実施時間3.75分間)
N.M.R (アセトン-d6) 7.5-7.3(m 5ArH) 7.2(d J 8.8Hz 2ArH) 7.0(d J 8.8Hz 2ArH) 6.9(d J 8.6Hz ArH) 6.35(s ArH) 6.1(d J 8.7Hz ArH) 3.85(s 3OCH3) 2.25(s 3CH3)
4-クロロ-6-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-ベンゼン-1,3-ジオール
LC保持時間2.37分間 [M+H]+ 332.2 (実施時間3.75分間)
N.M.R (アセトン-d6) 7.2(d J 8.8Hz 2ArH) 7.15(s ArH) 6.9(d J 8.8Hz 2ArH) 6.6(s ArH) 3.85(s 3OCH3) 2.25(s 3CH3)
4-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-6-フェネチル-ベンゼン-1,3-ジオール
LC保持時間2.56分間 [M+H]+ 402 (実施時間3.75分間)
LC保持時間1.61分間 [M+H]+ 522.6 (実施時間3.75分間)
N.M.R (アセトン-d6) 7.2(d J 8.8Hz 2ArH) 6.95(s ArH) 6.8(d J 8.8Hz 2ArH) 3.85(s 3OCH3) 3.75(s 2CH2) 3.65(s 2CH2) 2.9-2,0(br s 16 CH2) 2.3(s 3CH3) 2.25(s 3CH3) 2.2(s 3CH3)
テトラヒドロフラン(2.5ml)中の5-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール(154mg、0.28mmol)の溶液にn-ブチルリチウム (100μl)を、窒素雰囲気下、-78℃で加えた。溶液を-70℃で30分間撹拌し、オレンジ色の溶液を得た。イオンをメチル クロロホルメート(100μl、3当量)でクエンチし、室温まで30分間暖めた。この溶液を飽和塩化アンモニウム水(5ml)でクエンチした。その混合物を酢酸エチル(3×5ml)で抽出した。併せた抽出物を水(2×5ml)および食塩の飽和水溶液(5ml)で洗浄した。溶液を無水硫酸マグネシウムで乾燥し、濃縮した。粗生成物を、ヘキサン中の酢酸エチル(酢酸エチル20%〜60%の勾配)で溶出するシリカカラムクロマトグラフィーにより精製し、2,4-ビス-ベンジルオキシ-5-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-安息香酸 メチルエステル(72mg)を得た。
LC保持時間4.95分間 [M+H]+ 536.4 (実施時間7.5分間)
N.M.R (DMSO-d6) 7.8(s ArH) 7.55(d J 7.1Hz 2ArH) 7.4(t J 6.2Hz 2ArH) 7.35(d J 6.1Hz ArH) 7.3(m 3ArH) 7.1(m 4ArH) 7.0(s ArH) 6.9(d 8.8Hz 2ArH) 5.3(s 2CH2) 5.1(s 2CH2) 3.78(s OCH3) 3.76(s OCH3) 2.28(s CH3)
メタノール(2ml)/酢酸エチル(1ml)中の2,4-ビス-ベンジルオキシ-5-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-安息香酸 メチルエステル(72mg、0.13mmol)の溶液に、ギ酸アンモニウム(172mg、20当量)を窒素雰囲気下に加えた。10%パラジウム炭素(触媒)を加え、その懸濁液を60℃で一夜加熱した。その溶液を冷却した。酢酸エチル(5ml)を加え、溶液を水(2×5ml)および食塩の飽和水溶液(5ml)で洗浄した。その溶液を無水硫酸マグネシウムで乾燥して濃縮した。粗生成物を、ヘキサン中の酢酸エチル(酢酸エチル25%〜45%の勾配)で溶出するシリカカラムクロマトグラフィーにより精製し、2,4-ジヒドロキシ-5-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-安息香酸 メチルエステル(7.0mg)を得た。
LC保持時間2.49分間 [M+H]+ 356.3 (実施時間3.75分間)
N.M.R (CDCl3) δ= 10.85(s ArOH) 7.52(s ArOH) 7.12(d J8Hz 2ArH) 6.98(s ArH) 6.91(d J8Hz 2ArH) 6.45(s ArH) 3.78(s 3 OCH3) 3.71(s 3 OCH3) 2.21(s 3 CH3)
同様にして、実施例17〜20を、N-ホルミルピペリジン、フェニルチオイソシアネート、2-メトキシフェニルイソシアネートおよびベンズアルデヒドでそれぞれクエンチして製造した。最後の脱保護反応は、実施例23 (スキーム5の最終反応)で記載されているように三塩化ホウ素を用いて行った。実施例 21は実施例 16工程1からの副産物であった。記載した活性は、以下に記載のマラカイトグリーンアッセイで得られたものである。
LC保持時間2.73分間 [M+H]+ 359.2 (実施時間3.75分間)
δ (クロロホルム-d) 7.7(m 2ArH) 7.5(m 2ArH) 7.35(m 2ArH) 7.15(m 2ArH) 4.25(q J 7.1Hz 2CH2) 4.05(q J 7.1Hz 2 CH2) 1.35(t J 7.1Hz 3CH3) 1.15(t J 7.1Hz 3 CH3)
LC保持時間2.28分間 [M+H]+ イオンがない (実施時間3.75分間)
δ (クロロホルム-d) 7.2(m 3ArH) 7.1(m 2ArH) 6.85(d J 8.1Hz ArH) 6.3(d J 8.1Hz ArH) 6.2(s ArH) 3.85(s 2CH2)
3-[2,4-ビス-ベンジルオキシ-5-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-フェニル]-アクリル酸 tert-ブチルエステル
LC保持時間3.23分間 [M+H]+ 604.6 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.85(d J 16.1Hz CH) 7.6(s ArH) 7.4-7.25(m 8ArH) 7.05(d J 8.8Hz 2ArH) 6.9(m 2ArH) 6.8(d J 8.8Hz 2ArH) 6.5(s ArH) 6.35 (d J 16.1Hz CH) 5.05(s 2CH2) 4.75(s 2CH2) 3.75(s 3OCH3) 2.25(s 3CH3) 1.5(s 9CCH3)
3-[2,4-ジヒドロキシ-5-[4-(4-メトキシ-フェニル)-3-メチル-イソオキサゾール-5-イル]-フェニル]-アクリル酸
LC保持時間2.08分間 [M+H]+ 368.3 (実施時間3.75分間)
N.M.R (アセトン-d6) 7.85(d J 16.1Hz CH) 7.5(s ArH) 7.25(d J 8.8Hz 2ArH) 6.95(d J 8.8Hz 2ArH) 6.6(s ArH) 6.35 (d J 16.1Hz CH) 3.8(s 3OCH3) 2.25(s 3CH3)
5-(5-クロロ-2,4-ジヒドロキシフェニル)-4-(4-メトキシ-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
1-(5-クロロ-2,4-ジヒドロキシ-フェニル)-エタノン
LCMS:[M-H]+ 185.
1-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-エタノン
1H NMR (400MHz)は構造と一致した。
4-(2,4-ビス-ベンジルオキシ-5-クロロフェニル)-2-ヒドロキシ-4-オキソ-2-ブテン酸 エチルエステル
1H NMR (400 MHz、CDCl3) δ 1.2 (t、3H)、4.19 (q、2H)、5.05 (s、2H)、5.10 (s、2H)、6.50 (s、1H)、7.22-7.41 (m、10H)、7.97 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-クロロフェニル)-イソオキサゾール-3-カルボン酸 エチルエステル
LCMS:[M+H]+ 466、464 (37Cl35Cl). ). 1H NMR (400 MHz、CDCl3) δ 1.42 (t、3H)、4.42 (q、2H)、5.13 (s、2H)、5.14 (s、2H)、6.62 (s、1H)、7.01 (s、1H)、7.35-7.43 (m、10H)、8.00 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-クロロフェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 465、463 (37Cl、35Cl). 1H NMR (400 MHz、CDCl3) δ 1.25 (t、3H)、3.48 (m、2H)、5.10 (s、2H)、5.2 (s、2H)、6.59 (s、1H)、6.83 (brt、1H)、7.08 (s、1H)、7.30-7.41 (m、10H)、7.97 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-クロロフェニル)-4-ブロモ-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 543、541 (81Br、79Br). 1H NMR (400 MHz、CDCl3) δ 1.26 (t、1H)、3.50 (m、2H)、5.01 (s、2H)、5.12 (s、2H)、6.62 (s、1H)、6.74 (br t、1H)、2.28-7.41 (m、10H)、7.53 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-クロロフェニル)-4-(4-メトキシ-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 571、569 (37Cl、35Cl). 1H NMR (400 MHz、CDCl3) δ 1.21 (t、3H)、3.44 (m、2H)、3.79 (s、3H)、4.73 (s、2H)、6.45 (s、1H)、6.65 (t、1H)、6.80 (d、2H)、7.14 to 7.44 (m、8H)、6.95 (m 2H).
5-(5-クロロ-2,4-ジヒドロキシフェニル)-4-(4-メトキシ-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 391、389 (37Cl、35Cl). 1H NMR (400 MHz、d6-DMSO) δ 1.08 (t、3H)、3.22 (m、2H)、3.73 (s、3H)、6.59 (s 1H)、6.87 (d、1H)、7.13-7.17 (m、3H)、8.88 (br t、1H)、10.09 (s、1H)、10.62 (s、1H).
1-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-3-ヒドロキシ-2-ブテン-1-オン:
ケトン(15g)のEtOAc (200ml)溶液に、小片の金属ナトリウム(3.0g)を加えた。その懸濁液を室温で15分間撹拌し、次いで一夜加熱還流した。反応を酢酸でクエンチし、黄色沈殿物をろ過した。これをヘキサン中で磨砕し、淡黄色結晶を得た。
NMRはこれが所望の物質−殆どがエノールフォームであり、−少しの痕跡量がケトフォームであることを示した。
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-3-メチル-イソオキサゾール:
ジケトン(4.0g)を80%水性EtOH中に懸濁した。ヒドロキシルアミン 塩酸塩(3.4g)および酢酸ナトリウム(4.0g)を加え、2M NaOHでpHを8/9に調節した。その溶液を24時間還流した(極めてよく似たRf値によりTLCのよるモニターは困難)。この時間の後、1M HClでその溶液をpH5に酸性化し、水に注ぎ込んだ。白色の沈殿物をろ過し、水洗し、そしてヘキサンで磨砕し、白色固体を得た。
覚書;化合物は痕跡量の不純物を除去するために必要であればエーテルで洗浄することもできるが、通常必要でない。
NMRはこれが所望の物質であることを示した。
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-ヨード -3-メチル-イソオキサゾール:
イソオキサゾール(2g)を酢酸(24ml)および水(30ml)の混液中に入れる。一塩化ヨウ素(2g、過剰)を加え、その溶液を80℃で2〜3時間加熱した。室温に冷却後、Na2SO3 (亜硫酸ナトリウム)の10%水溶液(50ml)を加えた。その混合物から粘性のオレンジ色の固体/油を分離し、水洗した。次いで、アセトンに溶解してろ過した。真空下でアセトンを除去し、粘着性の(一夜で固化してオレンジ色の固体になる)オレンジ色油を得た。
NMRおよびLCMSはこれが所望の物質であることを示した。
LCMS tR = 9.06、MS m/z 510.4 [M+H]+
4-[3-[5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-3-メチル-イソオキサゾール-4-イル]-ベンジル]-モルホリン
4-クロロ-6-[3-メチル-4-(3-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-5-イル]-ベンゼン-1,3-ジオール
LCMS tR = 5.46、MS m/z 399.3 [M-H]-
実施例 28は以下に記載のように蛍光偏光試験において活性‘A’を有していた。
1-[3-[5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-3-メチル-イソオキサゾール-4-イル]-ベンジル]-ピペリジン-4-カルボン酸アミド
LCMS tR = 5.36、MS m/z 442.3 [M+H]+
実施例 29は以下に記載のように蛍光偏光試験において活性‘A’を有していた。
同様の方法で実施例30を製造した:
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-ヨード-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS tR = 8.75、MS m/z 589.1 [M+H]+
1-(3-ブロモ-フェニル)-4-メチル-ピペラジン
LCMS tR = 4.55、MS m/z 255.4/257.3 [M+H]+
1-メチル-4-[3-(4,4,5,5-テトラメチル-[1,3,2]ジオキサボロラン-2-イル)-フェニル]-ピペラジン
LCMS tR = 0.97、MS m/z 303.5 [M+H]+
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-[3-(4-メチル-ピペラジン-1-イル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-[3-(4-メチル-ピペラジン-1-イル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS tR = 5.58、MS m/z 457.3 [M+H]+
δH (d4-MeOH)、7.17 (1H、m、Ar-H)、7.09 (1H、s、Ar-H)、6.94 (1H、m、Ar-H)、6.80 (1H、m、Ar-H)、6.49 (1H、s、Ar-H)、3.13 (4H、t、NCH2CH2N-CH3)、2.69 (2H、q、CONHCH2CH3)、2.61 (4H、t、NCH2CH2N-CH3)、2.37 (3H、s、NCH2CH2N-CH3)、1.19 (3H、t、CONHCH2CH3)
実施例 31は以下に記載のように蛍光偏光試験において活性‘A’を有していた。
1-(4-ブロモ-フェニル)-4-メチル-ピペラジン
LC保持時間2.21分間 [M+H]+ 256 (実施時間3.75分間)
1-メチル-4-[4-(4,4,5,5-テトラメチル-[1,3,2]ジオキサボロラン-2-イル)-フェニル]-ピペラジン
LC保持時間1.83分間 [M+H]+ 303 (実施時間3.75分間)
LC保持時間0.39分間 [M+H]+ 258 (実施時間3.75分間)
LC保持時間1.65分間 [M+H]+ 270 (実施時間8分間)
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-(3-クロロ-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
[5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-(3-クロロ-フェニル)-イソオキサゾール-3-イルメチル]-エチル-アミン
LCMS (LCT) tR = 8.18、MS m/z 558.8 [M+H]+
実施例 39は以下に記載のように蛍光偏光試験において活性‘A’を有していた。
LC/MS:RT = 2.908分 567.3 (MH+)
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC/MS:RT = 2.365分 638.4 (MH+)
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC/MS:RT = 1.751分 458.2 (MH+)
実施例 41は以下に記載のように蛍光偏光試験において活性‘A’を有していた。
1-(2,4-ビス-ベンジルオキシ-フェニル)-エタノン
LC-MS [M+H]+ = 333
収率:51.2g (67%)
1-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-エタノン
LC-MS [M+H]+ = 411および413
収率:58.15g (92%)
4-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-2,4-ジオキソ-酪酸 エチルエステル
収率:69.24g (96%)
1H NMR (400 MHz、CDCl3) δ 1.27 (t、3H)、4.27 (q、2H)、5.13 (d、2H)、6.54 (s、1H)、7.37 (m、10H)、8.17 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-イソオキサゾール-3-カルボン酸 エチルエステル
収率:67.62g (99%)
1H NMR (400 MHz、CDCl3) δ 1.39 (t、3H)、4.41 (q、2H)、5.11 (d、2H)、5.15 (d、2H)、6.58 (s、1H)、6.99 (s、1H)、7.35 (m、10H)、8.16 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC-MS保持時間2.868分間 [M+H]+ = 507 & 509 (実施時間3.75 分間)
5-(2,4-ビス-ベンジルオキシ-5-スチリルフェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 531. 1H NMR (400 MHz、CDCl3) δ1.12 (t、3H)、3.37 (m、2H)、4.95 (s、2H)、5.07 (s、2H)、6.46 (s、1H)、6.70 (brt、1H). 7.11 (s、1H)、7.17 (d、1H)、7.23 (d、1H)、7.32-7.44 (m、15H)、8.09 (s、1H)
5-(2,4-ビス-ベンジルオキシ-5-フェネチルフェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 533. 1H NMR (400 MHz、CDCl3) δ1.26 (t、3H)、2.86-2.96 (m、4H)、3.49 (m、2H)、5.03 (s、2H)、5.18 (s、2H)、6.56 (s、1H)、6.81 (t、1H)、7.07 (s、1H)、7.15-7.20 (m、3H)、7.23-7.28 (m、2H)、7.31-7.42 (m、10H)、7.73 (s,1H)
5-(2,4-ビス-ベンジルオキシ-5-フェネチルフェニル)-4-ブロモ-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 613、611
5-(2,4-ビス-ベンジルオキシ-5-フェネチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LCMS:[M+H]+ 708
5-(2,4 -ジヒドロキシ-5-フェネチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド 塩酸塩
LCMS:[M+H]+ 528. 1H NMR (400 MHz、d6-DMSO) δ1.08 (t、3H)、2.60 (m、4H)、2.90-3.30 (m、6H)、3.67 (m、2H)、3.87 (m、2H)、4.30 (s、2H)、6.46 (s、1H)、6.84 (s、1H)、7.05-7.49 (m、5H)、7.40-7.68 (m、4H)、8.90 (brs、1H)、9.67 (s、1H)、9.89 (s、1H)、10.75 (brs、1H)
実施例 65は以下に記載のように蛍光偏光試験において活性‘A’を有していた。
3-(2,4-ビス-ベンジルオキシ-5-ブロモ-フェニル)-4-(4-メトキシ-フェニル)-5-メチル-イソオキサゾール
LC保持時間5.55分間 [M+H]+ 556.0および558.0 (実施時間8.00分間)
N.M.R (クロロホルム-d) 7.64 (s ArH) 7.356.76 (m 14 ArH) 6.34 (s ArH) 4.90 (s 2CH2) 4.60 (s 2CH2) 3.79 (s 3CH3 ) 2.46 (s 3CH3 )
4-ブロモ-6-[4-(4-メトキシ-フェニル)-5-メチル-イソオキサゾール-3-イル]-ベンゼン-1,3-ジオール
LC保持時間2.52分間 [M+H]+ 376.1および378.1 (実施時間3.75分間)
N.M.R (DMSO-d6) 10.40 (s OH) 9.69 (s OH) 7.22 (ArH) 7.10-6.89(m 4ArH) 6.5 (s ArH) 3.7(s OCH3) 2.46(s CH3)
この化合物はHsp90蛍光偏光試験において活性‘A’を有していた。
1-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-エタノン
LC保持時間2.74分間 [M+H]+ 209.1 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.35(s ArH) 6.05(s ArH) 7.35(m 2ArH) 2.35(s 3CH3) 1.15(s 9 CH3)
1-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-エタノン
その油を2-メチル-2-プロパノール(100ml)中に採取し、カリウムtert-ブトキシド(7.5g、67mmol)を加え、淡黄色沈殿物を得、ベンジルブロマイド(8ml、67mmol)を加え混合物を還流下に〜1時間加熱する。得られた懸濁液を冷却し、水(250ml)中に注ぎ、淡オレンジ色沈殿物を得る。固体をろ取し、水洗した。その固体を酢酸エチル(150ml)中に採取し、水(2×200ml)および食塩の飽和水溶液(100ml)で洗浄した。その溶液を無水硫酸ナトリウムで乾燥し、オレンジ色の半固体になるまで濃縮し、メタノールを用いて磨砕して淡ピンク色の固体を得た。固体をろ取し、真空乾燥(40℃)し、淡ピンク色の粉末として1-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-エタノン(9.1g、36%)を得た。
LC保持時間3.03分間 [M+H]+ 389.3 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.65(s ArH) 7.25-7.15(m 10ArH) 6.35(s ArH) 4.95(s 2CH2) 4.9(s 2 CH2) 2.4(s 3CH3) 1.2(s 9 CH3)
4-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-2-ヒドロキシ-4-オキソ-2-ブテン酸 エチルエステル
N.M.R (クロロホルム-d) 8.0(s ArH) 7.5-7.35(m 11ArH) 6.6(s ArH) 5.2(s 2CH2) 5.15(s 2 CH2) 4.3(q J 7.1Hz 2 CH2) 1.4(s 9 CH3) 1.25(t J 7.1Hz 3CH3)
5-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルエステル
LC保持時間3.13分間 [M+H]+ 486.5 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.85(s ArH) 7.4-7.25(m 10ArH) 6.9(s ArH) 6.5 (s ArH) 5.1(s 2CH2) 5.0(s 2 CH2) 4.35(q J 7.1Hz 2 CH2) 1.4(s 9 CH3) 1.35(t J 7.1Hz 3CH3)
5-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間3.02分間 [M+H]+ 485.3 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.8(s ArH) 7.4-7.2(m 10ArH) 7.0(s ArH) 6.75(br t J 5.4Hz NH) 6.5 (s ArH) 5.1(s 2CH2) 5.0(s 2 CH2) 3.4(dq J 5.4Hz、7.1Hz 2 CH2) 1.35(s 9 CH3) 1.15(t J 7.1Hz 3CH3)
5-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-4-ヨード-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間3.07分間 [M+H]+ 611.2 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.45-7.25(m 11ArH) 6.8(br t J 5.4Hz NH) 6.6(s ArH) 5.05(s 4CH2) 3.5(dq J 5.4Hz、7.1Hz 2 CH2) 1.35(s 9 CH3) 1.2(t J 7.1Hz 3CH3)
5-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-4-(4-ホルミル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間3.01分間 [M+H]+ 589.4 (実施時間3.75分間)
N.M.R (クロロホルム-d) 9.75(s CHO) 7.5(d J 6.9Hz 2 ArH) 7.2(d J 6.9Hz 2 ArH) 7.15-7.0(m 8ArH) 6.8(m 2 ArH) 6.65 (br t J 5.4Hz NH) 6.2(s ArH) 4.8(s 2CH2) 4.5(s 2 CH2) 3.2(dq J 5.4Hz、7.1Hz 2 CH2) 1.1(s 9 CH3) 1.05(t J 7.Hz 3CH3)
5-(2,4-ビス-ベンジルオキシ-5-tert-ブチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間2.56分間 [M+H]+ 660.8 (実施時間3.75分間)
N.M.R (クロロホルム-d) 7.35-7.05(m 15ArH) 6.7 (br t J 5.4Hz NH) 6.4(s ArH) 4.9(s 2CH2) 4.75(s 2 CH2) 3.6(t J 4.5Hz 4 CH2) 3.(s 2 CH2) 3.35(dq J 5.4Hz、7.1Hz 2 CH2) 2.35(br s 4 CH2) 1.15(t J 7.1Hz 3CH3) 1.1(s 9 CH3)
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間1.97分間 [M+H]+ 480.5 (実施時間3.75分間)
N.M.R (DMSO-d6) 8.8 (t J 5.6Hz NH) 7.25(d J 7.2Hz 2ArH) 7.15(d J 7.2Hz 2ArH) 6.7(s ArH) 6.45(s ArH) 3.45(br s 4 CH2) 3.2(dq J 5.6Hz、7.2Hz 2 CH2) 2.3(br s 4 CH2) 1.1(s 9 CH3) 1.05(t J 7.2Hz 3CH3)
この化合物はHsp90蛍光偏光試験において活性‘A’を有していた。
1-(2,4-ビス-ベンジルオキシ-フェニル)-エタノン
LC保持時間2.704分 [M+H]+ 333.3
2,4-ビス-ベンジルオキシ-1-イソプロペニル-ベンゼン
Rf保持時間0.722、3:1 ヘキサン:EtOAc.
4-イソプロピル-ベンゼン-1,3-ジオール
LC保持時間2.088分 [M+H]+ 153.1
1-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-エタノン
LC保持時間2.633分 [M+H]+ 195.1
1-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-エタノン
LC保持時間3.575分 [M+H]+ 375.2
4-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-2-ヒドロキシ-4-オキソ-2-ブテン酸 エチルエステル
LC保持時間3.057分 [M+H]+ 475
5-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルエステル
LC保持時間3.059分 [M+H]+ 472
5-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間2.979分 [M+H]+ 471.3
5-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-4-ヨード-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間2.975分 [M+H]+ 597.2
5-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-4-ヨード-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間2.981分 [M+H]+ 575.3
5-(2,4-ビス-ベンジルオキシ-5-イソプロピル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間4.42分 [M+H]+ 646.2 方法B
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間1.991分 [M+H]+ 466.3
この化合物はHsp90蛍光偏光試験において活性‘A’を有していた。
リン酸 4-クロロ-5-(ジエトキシ-ホスホリルオキシ)-2-[3-エチルカルバモイル-4-(4-メトキシ-フェニル)-イソオキサゾール-5-イル]-フェニルエステル ジエチルエステル
Rf = 0.35、1H NMRδ= 7.95 (1H、s、幅広い);7.74 (1H、s);7.55 (1H、s);7.32 (2H、d、J = 9.0 Hz);6.90 (2H、d、J = 9.0 Hz);4.30 (8H、q);3.80 (3H、s);3.40 (2H、q);1.35 (12H、t)および1.25 (3H、t). LCMS:(M+1)+ = 661.1 (RT = 7.60分)
1-(2,4-ジヒドロキシ-フェニル)-2-メチル-プロパン-1-オン
LC保持時間2.279 分 [M+H]+ 181.1
4-イソブチル-ベンゼン-1,3-ジオール
NMRは構造と矛盾がない。
1-(2,4-ジヒドロキシ-5-イソブチル-フェニル)-エタノン
NMRは構造と矛盾がない。
1-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-エタノン
LC保持時間3.030 分 [M+H]+ 389.3
4-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-2,4-ジオキソ-酪酸 エチルエステル
LC保持時間3.254 分 [M+H]+ 489.3
5-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルエステル
LC保持時間3.261 分 [M+H]+ 486.3
5-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間3.112 分 [M+H]+ 485.3
5-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-4-ヨード-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間3.089 分 [M+H]+ 611.2
5-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-4-(4-ホルミル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間5.57 分 [M+H]+ 589.1 方法 B
5-(2,4-ビス-ベンジルオキシ-5-イソブチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間4.53 分 [M+H]+ 660.2 方法 B
5-(2,4-ジヒドロキシ-5-イソブチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
LC保持時間1.902 分 [M+H]+ 480.3
この化合物はHsp90蛍光偏光試験において活性‘A’を有していた。
N-[5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-フルオロ-フェニル)-イソオキサゾール-3-イルメチル]-アセトアミド
5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-(4-フルオロ-フェニル)-イソオキサゾール-3-カルボン酸アミド
LCMS (LCQ) tR = 8.70、MS m/z 529.1 [M+H]+
LCMS (LCQ) tR = 7.54、MS m/z 515.2 [M+H]+
メタンスルホニルクロライド(17μl、1.1当量)およびトリエチルアミン(30μl、1.1当量)の添加前に、C-[5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-(4-フルオロ-フェニル)-イソオキサゾール-3-イル]-メチルアミン(100mg、0.19mmol)をDCM (3ml)に溶解した。この溶液を、真空中で蒸発乾固し、青色残渣としてベンジル保護した粗生成物(90mg)を残させる前に、室温で一夜撹拌した。これを、上記の三塩化ホウ素を用いる標準の方法を用いて脱保護し、分取TLC (DCM中10%エタノール)およびエーテルによるシリカのソックスレー抽出で精製し、無色に近い固体として純粋な化合物(8mg、10%収率)を得た。
LCMS (LCQ) tR = 6.65、MS m/z 411.2 [M-H]-
δH (d4-MeOH)、7.19 (2H、m、Ar-H)、7.04 (1H、s、Ar-H)、7.03 (2H、m、Ar-H)、6.34 (1H、s、Ar-H)、4.27 (2H、s、CH2NH)、2.81 (3H、s、SO2CH3).
C-[5-(2,4-ビス-ベンジルオキシ-5-クロロ-フェニル)-4-(4-フルオロ-フェニル)-イソオキサゾール-3-イル]-メチルアミン(100mg、0.19mmol)のDCM溶液に、無水酢酸(130μl、7.0当量)およびトリエチルアミン(81μl、3.0当量)を加えた。この溶液を室温で、アミンが消費されるまで撹拌した。溶媒を真空中で除去し、帯黄色油状のベンジル保護粗生成物が残った。これを上記の三塩化ホウ素を用いる標準の方法を用いて脱保護し、分取TLCおよびエーテルによるシリカのソックスレー抽出で精製し、無色の固体として純粋な化合物(10mg、14%収率)を得た。
LCMS (LCQ) tR =6.57、MS m/z 377.1 [M+H]+
δH (d4-MeOH)、7.17 (2H、m、Ar-H)、7.01 (1H、s、Ar-H)、6.98 (2H、m、Ar-H)、6.32 (1H、s、Ar-H)、4.37 (2H、s、CH2NH)、1.77 (3H、s、COCH3).
5-(5-エチル-4-ヒドロキシ-2-メトキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド(83);5-(5-エチル-2-ヒドロキシ-4-メトキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド(84);5-(5-エチル-2,4-ジメトキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド(85)
(83):LCMS (LCT) tR = 4.95、MS m/z 466.4 [M+H]+
(84):LCMS (LCT) tR = 5.14、MS m/z 466.4 [M+H]+
(85):LCMS (LCT) tR = 5.45、MS m/z 480.4 [M+H]+
NMRデータは帰属と矛盾しなかった。
メチル 2-ベンゾイルオキシ-5-クロロ-ベンゾエート
1H NMR (d6-アセトン) δ= 7.73 (1H、d);7.60 - 7.30 (1H + 5H、m);7.28 (1H、d);5.30 (2H、s)および3.90 (3H、s)
1-(2-ベンジルオキシ-5-クロロ-フェニル)-2-(トリフェニル-λ5-ホスファニリデン)-エタノン
Rf = 0.43. 1H NMR (d6-アセトン) δ= 7.80-7.52 (20H、m);7.40-7.20 (1H+1H+1H、m);5.25 (2H、s);4.72 (1H、s、trans-H)および4.62 (1H、s、cis-H). LCMS:(M+1)+ = 521.2 (RT = 5.94分)
エチル 4-(2-ベンジルオキシ-5-クロロ-フェニル)-2,4-ジオキソ-3-(トリフェニル-λ5 ホスファニリデン)-ブチレート
Rf = 0.88. 1H NMR (d6-アセトン) δ= 7.75 - 7.40 (15H、m);7.30 (1H、dd);7.15 (1H、d);7.05 (1H、d);5.10 (2H、s);3.60 (2H、q)および1.10 (3H、s). LCMS:(M+1)+ = 621.2 (RT = 6.49分)
エチル 3-(2-ベンゾイルオキシ-5-クロロ-ベンゾイル)-3-ブロモ-3H-アジリン-2-カルボキシレート
Rf = 0.73 (EtOAc:ヘキサン 1:2). 1H NMR (d6-アセトン) δ= 7.80 (1H、d);7.60 (1H、dd);7.40 (5H、m);7.30 (1H、d);5.20 (2H、s);4.10 (2H、q)および1.00 (3H、t). LCMS:(M+1)+ = 438.0 (RT = 7.32分)
エチル 5-(2-ベンゾイルオキシ-5-クロロ-フェニル)-4-ブロモ-イソオキサゾール-3-カルボキシレート
Rf = 0.73 (蛍光). 1H NMR (d6-アセトン) δ= 7.60 (1H、d);7.50 (1H、dd);7.40 (1H、d);7.30 (5H、m);5.25 (2H、s);4.42 (2H、q)および1.40 (3H、t). LCMS:(M+1)+ = 438.0 (RT = 7.09分)
エチル 5-(2-ベンジルオキシ-5-クロロ-フェニル)-4-ブロモ-イソオキサゾール-3-カルボキサミド
Rf = 0.39 (EtOAc:ヘキサン/1:4) 1H NMR (d6-アセトン) δ= 8.10 (1H、s、幅広い);7.50 (1H、d);7.45 - 7.35 (1H + 1H、m);7.25 (5H、m);5.20 (2H、s);3.40 (2H、q)および1.20 (3H、t). LCMS:(M+1)+ = 437.1 (RT = 6.57分)
エチル 5-(2-ベンジルオキシ-5-クロロ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボキサミド
Rf = 0.44 (EtOAc). 1H NMR (d6-アセトン) δ= 8.25 (1H、s、幅広い);7.60 (1H、d);7.55 (1H、dd);7.45 (1H、d);7.30 - 6.90 (9H、m);5.00 (2H、s);3.55 (4H、m);3.45 (2H + 2H、s + q);2.30 (4H、m)および1.20 (3H、t). LCMS:(M+1)+ = 532.2 (RT = 4.39分)
エチル 5-(5-クロロ-2-ヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボキサミド
1H NMR (d4-MeOD) δ= 7.60 (2H、d);7.50 - 7.30 (1H + 1H + 1H、m);7.00 (2H、d);3.70 (4H、m);3.60 (2H、s);3.50 (2H、q);2.60 (4H、m)および1.25 (3H、t). LCMS:(M+1)+ = 442.2 (RT = 3.54分)
4-ヒドロキシ異性体を、以下のように、2-ヒドロキシの相対物と類似の方法で製造した
:
メチル 4-ベンゾイルオキシ-3-クロロ-ベンゾエート
1H NMR (d6-アセトン) δ= 8.00 (1H、d);7.95 (1H、dd);7.60 - 7.40 (5H、m);7.35 (1H、d);5.40 (2H、s)および3.90 (3H、s).
1-(4-ベンジルオキシ-3-クロロ-フェニル)-2-(トリフェニル-λ5-ホスファニリデン)-エタノン
Rf = 0.31 (EtOAc:ヘキサン/1:1). 1H NMR (d6-アセトン) δ= 8.05 (1H、d);7.90 (1H、dd);7.85 - 7.35 (20H、m);7.20 (1H、d);5.30 (2H、s);4.60 (1H、s、trans-H)および4.50 (1H、s、cis-H). LCMS:(M+1)+ = 521.2 (RT = 5.29分)
エチル 4-(4-ベンジルオキシ-3-クロロ-フェニル)-2,4-ジオキソ-3-(トリフェニル-λ5 ホスファニリデン)-ブチレート
1H NMR (d6-アセトン) δ= 8.00 - 7.35 (22H、m);7.20 (1H、d);5.35 (2H、s);3.55 (2H、q)および1.14 (3H、s). LCMS:(M+1)+ = 621.2 (RT = 7.29分)
エチル 3-(4-ベンゾイルオキシ-3-クロロ-ベンゾイル)-3-ブロモ-3H-アジリン-2-カルボキシレート
Rf= 0.24 (EtOAc:ヘキサン/1:6). 1H NMR (d6-アセトン) δ= 8.00 (1H、d);7.90 (1H、dd);7.50 (1H、d);7.40 (5H、m);5.40 (2H、s);4.05 (2H、q)および0.95 (3H、t). LCMS:(M+1)+ = 438.1 (RT = 7.27分)
エチル 5-(4-ベンゾイルオキシ-3-クロロ-フェニル)-4-ブロモ-イソオキサゾール-3-カルボキシレート
Rf = 0.26 (蛍光) (EtOAc:ヘキサン/1:4). 1H NMR (d6-アセトン) δ= 8.00 (1H、d);7.90 (1H、dd);7.50 (1H、d);7.40 (5H、m);5.35 (2H、s);4.45 (2H、q)および1.40 (3H、t). LCMS:(M+1)+ = 438.0 (RT = 7.39分)
エチル 5-(4-ベンジルオキシ-3-クロロ-フェニル)-4-ブロモ-イソオキサゾール-3-カルボキサミド
Rf = 0.53 (EtOAc:ヘキサン/1:2). 1H NMR (d6-アセトン) δ= 8.15 (1H、s、幅広い);8.00 (1H、d);7.90 (1H、dd);7.50 (1H、d);7.40 (5H、m);5.32 (2H、s);3.42 (2H、q)および1.20 (3H、t)
エチル 5-(4-ベンジルオキシ-3-クロロ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボキサミド
エチル 5-(3-クロロ-4-ヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボキサミド
1H NMR (d4-MeOD) δ= 7.70 (2H、d);7.60 (1H、d);7.45 (1H+1H、m);7.00 (2H、d);3.80 (4H、m);3.75 (2H、s);3.50 (2H、q);2.82 (4H、m)および1.25 (3H、t). LCMS:(M+1)+ = 442.2 (RT = 4.47分)
3-(4-ブロモ-フェニル)-6-クロロ-7-ヒドロキシ-4-オキソ-4H-クロメン-8-カルブアルデヒド
LCMS (LCQ) tR = 8.27、MS m/z 377.3 / 379.2 [M-H]-
3-[4-(4-ブロモ-フェニル)-イソオキサゾール-5-イル]-5-クロロ-2,6-ジヒドロキシ-ベンズアルデヒド
1H NMR (d6-DMSO) δ= 9.83 (1H、s);8.70 (1H、s);8.21 (1H、s);7.78 (2H、d)および7.68 (2H、s). LCMS:(M+1)+ = 394.1 (RT = 8.60分)
1-(5-エチル-2,4-ジヒドロキシ-フェニル)-2-(4-フルオロ-フェニル)-エタノン
Rf = 0.4 (EtOAc:n-ヘキサン/1:3). 1H NMR (d6-アセトン) δ= 7.80 (1H、s);7.35 (2H、m);7.00 (1H、m);6.35 (1H、s);4.35 (2H、s);2.55 (2H、
q)および1.10 (3H、t).
4-(5-エチル-2,4-ジヒドロキシ-フェニル)-3-(4-フルオロ-フェニル)-2,4-ジオキソ-酪酸 エチルエステル
Rf = 0.22 (EtOAc:n-ヘキサン/1:2). LCMSはそれが所望の物質[(M-1)- = 373.1、RT = 7.27]と環化したクロメンカルボキシレート[(M-1)- = 355.4、RT = 7.83]の約6:1の比の混合物であることを示す。試料の僅かな量をスペクトル分析のために分取TLCで精製した。
1H NMR (d6-アセトン) δ= 7.75 (1H、s);7.30 (2H、m);7.00 (1H、m);6.45 (1H、s);4.65 (1H、s);4.25 (2H、q);2.55 (2H、q)および1.10 (6H、t)
6-エチル-3-(4-フルオロ-フェニル)-7-ヒドロキシ-4-オキソ-4H-クロメン-2-カルボン酸 エチルエステル
Rf = 0.43 (EtOAc:n-ヘキサン/1:2). LCMS:(M + 1)+ = 357.3 (RT = 7.83). 1H NMR (d6-アセトン) δ= 9.75 (1H、s);7.80 (1H、s);7.25 (2H、m);7.10 (1H、m);6.90 (1H、s);4.05 (2H、q);2.70 (2H、q);1.20 (3H、t)および0.95 (3H、t)
6-エチル-3-(4-フルオロ-フェニル)-7-メトキシ-4-オキソ-4H-クロメン-2-カルボン酸 エチルエステル
δH (CDCl3)、7.96 (1H、s、Ar-H)、7.27 (2H、m、Ar-H)、7.12 (2H、m、Ar-H)、6.92 (1H、s、Ar-H)、4.16 (2H、q、CO2CH2CH3 )、3.95 (3H、s、OCH3)、2.71 (3H、q、CH2CH3)、1.24 (3H、t、CO2CH2CH3)、1.04 (3H、t、CH2CH3)
5-(5-エチル-2-ヒドロキシ-4-メトキシ-フェニル)-4-(4-フルオロ-フェニル)-イソオキサゾール-3-カルボン酸 ヒドロキシアミド
LCMS (LCT) tR = 6.54、MS m/z 373.17 [M+H]+
δH (d6-アセトン)、10.73 (1H、幅広い s)、8.59 (1H、幅広い s)、7.39 (2H、m、Ar-H)、7.07 (2H、m、Ar-H)、7.00 (1H、s、Ar-H)、6.55 (1H、s、Ar-H)、3.82 (3H、s、OCH3)、2.48 (2H、q、CH2CH3)、1.30 (1H、幅広い s)、1.01 (3H、t、CH2CH3).
5-(5-エチル-2,4-ジヒドロキシ-フェニル)-4-(4-フルオロ-フェニル)-イソオキサゾール-3-カルボン酸 ヒドロキシアミド
LCMS (LCT) tR = 5.63、MS m/z 359.13 [M+H]+
δH (d6-アセトン)、10.72 (1H、幅広い s、CONH)、8.69 (1H、幅広い s、Ar-OH)、8.59 (1H、幅広い s、Ar-OH)、7.39 (2H、m、Ar-H)、7.06 (2H、m、Ar-H)、6.99 (1H、s、Ar-H)、6.52 (1H、s、Ar-H)、2.49 (2H、q、CH2CH3)、1.31 (1H、幅広い s)、1.08 (3H、t、CH2CH3).
Hsp90の内在性のATPアーゼ活性は、モデル系として酵母のHSP90を用いて測定できる。無機ホスフェートの測定に対してマラカイトグリーンの使用に基づくアッセイを、ここの実施例の化合物のいくつかのHSP90阻害活性試験に用いた。
材料
化学薬品は市販品で最高純度のものであり、全ての水溶液はAR水を用いて調製する。無機ホスフェートの混入を最小限にする必要性から、分析に使用される溶液および装置に注意を払うべきである。ガラス製品およびpHメータは、蒸留された水または脱イオンされた水で使用前に2度洗浄し、可能な限りどんな場合でも、プラスチック製品を使用すべきである。全ての操作に対して手袋を着用した。
(2) (a) 100mM Tris-HCl、pH7.4 (b) 150mM KCl (c) 6mM MgCl2のアッセイ緩衝液。室温で貯蔵する。
(3) 0.0812%(w/v)マラカイトグリーン(M 9636、シグマアルドリッチ社、Poole、UK)。室温で貯蔵する。
(4) 沸騰水中2.32%(w/v)ポリビニルアルコールUSP(P 1097、シグマアルドリッチ社、Poole、UK) (コメント1参照)、冷却して室温で貯蔵する。
(6) 34%(w/v)クエン酸ナトリウム、室温で貯蔵する。
(7) 100mM ATP2ナトリウム塩、特別品質(47699、シグマアルドリッチ)。-20℃で貯蔵する。
(8) E.coliにより発現された酵母HSP90蛋白質、95%以上に精製し(例えば、Panaretouら、1998参照)、50μLに分割して-80℃で貯蔵する。
1.試験化合物をAR水中500μMに希釈(DMSO濃度は2.5%である)。これらの化合物の2.5μlを直接、娘プレートからアッセイプレートへ移し、最終アッセイ濃度を100μMにする。12ポイントのIC50値を得るために、1:2の連続希釈を行い100μMから97.6nMの範囲のアッセイ濃度(2.5% DMSO)を作成し、各濃度の2.5μlをアッセイプレートへ移した。アッセイプレートの列1は、ネガティブコントールとして化合物を含まないものとする。化合物を含まないさらなる行を、バックグラウンドとしても使用する。
3.緩衝液の5μlをバックグラウンドの行に加える。
4.アッセイ緩衝液で酵素試料を1.05μMに希釈し、5μlずつ各化合物ウェルおよびネガティブコントロールの列に分割する。
5.ウェルの底に試薬を集め、プレートシールでプレートを覆い、37℃で一晩インキュベートする。
7.反転させて混合し、色が褐色から山吹色に変わるまで、約1時間放置する。
8.マラカイトグリーン試薬の40μlを各ウェルに加え、色が生じるように5分間放置する。
10.プレートシールで再度覆い、プレート振盪器で少なくとも15分間振盪する。
11.適当なプレートリーダー(例えば、Victor、Perkin Elmer Life Sciences、Milton Keynes、UK)を使って620nmでの吸光度を測定する。これらの条件で、対照の吸光度は0.9〜1.4であり、バックグラウンドは0.2〜0.35であり、そして、信号対雑音比〜12を与える。これらの条件を用いて得られたデータから計算されたZ'因子は、0.6〜0.9の間である。
(1) (1) ポリビニルアルコールは沸騰水に溶け難く、2〜3時間の撹拌を必要とする。
(2) マラカイトグリーン試薬とクエン酸ナトリウムの添加時間の間隔は、ATPの非酵素的加水分解を少なくするために、できるだけ短く保つべきである。一度クエン酸ナトリウムが加えられれば、色は室温で4時間まで安定である。
(4) アッセイ条件の時間、蛋白質および基質濃度は、信号対雑音格差を保持しながら、最小限の蛋白質濃度を達成するように最適化された。
(5) 信号対雑音比(S/N)は次の式:
(S-B)/ √((S の SD)2 + (B の SD)2
を用いて計算される。
増殖阻害分析も、HSP90阻害剤候補の分析に使用された。
1日目
1) 血球計数器により細胞数を決定する。
2) 8チャンネルマルチピペッターを用いて、細胞懸濁液(3600細胞/ウェルまたは2×104細胞/ml)の160μlを96-ウェルマイクロタイタープレートの各ウェルに加える。
3) CO2インキュベーター内で37℃で一晩インキュベートする。
4) 薬物の貯蔵溶液を調製し、各薬物の連続希釈を媒体中で行い、ウェル中に最終濃度のものを作成した。
5) マルチピペッターを用いて、薬物の40μl(5×最終濃度で)を四重のウェルに加える。
6) 対照ウェルは96ウェルプレートのいずれかの端であり、ここに媒体の40μlを加える。
7) CO2インキュベーター中で4日間(48時間)、プレートをインキュベートする。
8) 媒体を流しに捨て、プレートを10%氷冷トリクロロ酢酸(TCA)中にゆっくりと浸す。氷上で約30分間放置する。
9) プレートを水道水浴に浸した後、それを捨てることによって、プレートを水道水で3回洗浄する。
10) インキュベーター中で乾燥する。
12) 結合しなかったSRB染色剤を1%酢酸で4回洗浄して洗い流す。
13) インキュベーター中でプレートを乾燥する。
14) 10mMのTrisベースの100μlを用いてSRBを可溶化し、プレートをプレート振盪器の上に5分間置く。
16) 対数薬物濃度に対する吸光度%をプロットし、IC50を決定する。
蛍光偏光試験
蛍光偏光[蛍光異方性としても知られている]は、溶液中の蛍光発光種の回転を測定する。この場合、分子が大きいほど、蛍光発光をより偏光させる。蛍光体が偏光で励起されるときに、発光もまた偏光される。分子サイズは蛍光発光の偏光に比例する。
試験化合物をアッセイプレートに加え、平衡状態にし、その異方性を再度測定する。異方性の変化は、化合物のHSP90との競合的な結合(それによりプローブが遊離する)に由来する。
試薬は市販品で最高純度のものであり、全ての水溶液はAR水を用いて調製される。
1) コスター 96-ウェル ブラックアッセイプレート#3915。
2) (a)100mM Tris pH7.4; (b)20mM KCl; (c)6mM MgCl2のアッセイ緩衝液、室温で保存。
4) 100%DMSO中の20mMプローブ貯蔵濃度。暗所、RTで貯蔵。作業濃度はAR水で希釈し200nMであり、4℃で貯蔵。アッセイでの最終濃度は80nM。
5) E.coliにより発現されたヒト全長HSP90蛋白質、95%以上に精製し (例えば、Panaretouら、1998参照)、50μLに分割して-80℃で保存。
1) 100μl 1×緩衝液をウェル11Aおよび12A(=FP BLNK)に加える。
2) アッセイ混合物を調製−プローブが光感受性なので、全試薬はバケツに蓋をして氷上で保存される。
・1×Hsp90 FP 緩衝液 10 ml 1×
・BSA 10mg/ml (NEB) 5.0 μl 5μg/ml
・プローブ200μM 4.0 μl 80 nM
・ヒト全長Hsp90 6.25μl 200 nM
3) 全ての他のウェルに100μlのアッセイ混合物を分割
4) プレートで覆い、平衡状態にするために暗所、室温で20分間放置
1) きれいな96-ウェルv底プレート−{#VWR007/008/257}のウェルB1〜H11に100%DMSO 10μlを加える。
2) ウェルA1〜A11に100%DMSO 17.5μlを加える。
3) 2.5μlのcpdをA1に加える。これはcpds 20mMと仮定して、2.5mM{50×}貯蔵cpdを与える。
5) 列12を除いた行Aから行Bに5μlを移す。十分に混合。
6) 行Bから行Cへ5μlを移す。十分に混合。
7) 行Gまで繰り返す。
9) これにより50μM〜0.07μMの1×3の一連の希釈ができる。
10) ウェルB12に100μM標準化合物溶液20μlを調製する。
11) 最初のインキュベーション後、アッセイプレートをFusion (登録商標) a-FP plate reader (Packard BioScience、Pangbourne、Berkshire、UK)で読み取る。
13) Z'因子は0対照および陽性ウェルから計算される。それは典型的に0.7〜0.9の値を与える。
本発明、および本発明が属する技術分野の状況を、より十分に記載し、開示するために、多くの刊行物を上で引用している。これら参考文献の完全な引用を以下に示す。これらの参考文献の各々が、本明細書の中で完全に言及され、ここに組み込まれている。
Bijlmakers M-JJE, Marsh M. 2000 "Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56lck", Molecular Biology of the Cell, Vol. 11(5), pp. 1585-1595.
Bucci M; Roviezzo F; Cicala C; Sessa WC, Cirino G. 2000 "Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo", Brit. J. Pharmacol., Vol 131(1), pp. 13-16.
Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lozenzino LおよびRosen N. 2001 "A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells", Chem. Biol., Vol. 8, pp. 289-299.
Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DBおよびToft DO. 2000 "The HSP90-related protein TRAP1 is a mitochondrial protein with distinct functional properties", J. Biol. Chem., Vol. 5, pp. 3305-3312.
Fuller W, Cuthbert AW. 2000 "Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular Chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate", J. Biol. Chem.;Vol 275(48), pp. 37462-37468.
Hoang AT, Huang J, Rudra-Gonguly N, Zheng J, Powell WC, Rabindron SK, Wu CおよびRoy-Burman P. 2000 "A novel association between the human heat shock transcription factor I (HSF1) and prostate adenocarcinoma, Am. J. Pathol., Vol. 156, pp. 857-864.
Hur E, Kim H-H, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee M-O, Park H. 2002 "Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1α/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol", Mol. Pharmacol., Vol 62(5), pp. 975-982.
Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RCおよびLuqmani YA. 1992 "Clinical and biological significance of HSP89a in human breast cancer", Int. J. Cancer, Vol. 50, pp. 409-415.
Jolly CおよびMorimoto RI. 2000 "Role of the heat shock response and molecular chaperones in oncogenesis and cell death", J. Natl. Cancer Inst., Vol. 92, pp. 1564-1572.
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BAおよびHarrap KR. 1993 "Preclinical antitumour evaluation of bis-acetalo-amino-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug", Cancer Research, Vol. 53, pp. 25812586.
Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo, H. 2001 "A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts", Jap. J. Cancer Res., Vol 92(12), 1342-1351.
Lebeau J, Le Cholony C, Prosperi MTおよびGoubin G. 1991 "Constitutive overexpression of 89 kDa heat shock protein gene in the HBL100 mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene", Oncogene, Vol. 6, pp. 1125-1132.
Marcu MG, Schulte TWおよびNeckers L. 2000b "Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins", J. Natl. Cancer Inst., Vol. 92, pp. 242-248.
Neckers L, Schulte TWおよびMomnaaugh E. 1999 "Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity", Invest. New Drugs, Vol. 17, pp. 361-373.
Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PWおよびPearl LH. 1998 "ATP binding and hydrolysis are essential to the function of the HSP90 molecular chaperone in vivo", EMBO J., Vol. 17, pp. 4829-4836.
Pratt WB. 1997 "The role of the HSP90-based chaperone system in signal transduction by nuclear receptors and receptors signalling via MAP kinase", Annu. Rev. Pharmacol. Toxicol., Vol. 37, pp. 297-326.
Prodromou CおよびPearl LH. 2000a "Structure and in vivo function of HSP90", Curr. Opin. Struct. Biol., Vol. 10, pp. 46-51.
Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE, Roe SM, Piper PWおよびPearl LH. 2000b "The ATPase cycle of HSP90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains", EMBO J., Vol. 19, pp. 4383-4392.
Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PWおよびPearl LH. 1999 "Structural basis for inhibition of the HSP90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin", J. Med. Chem., Vol. 42, pp. 260-266.
Rutherford SLおよびLindquist S. 1998 "HSP90 as a capacitor for morphological evolution. Nature, Vol. 396, pp. 336-342.
Schulte TW, Akinaga S, Soga S, Sullivan W, Sensgard B, Toft DおよびNeckers LM. 1998 "Antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamcyin", Cell Stress and Chaperones, Vol. 3, pp. 100-108.
Sittler etal, 2001, Hum. Mol. Genet., Vol.10, pp.1307.
Smith DF. 2001 "Chaperones in signal transduction", in: Molecular chaperones in the cell (P Lund, ed.; Oxford University Press, Oxford and NY), pp. 165178.
Song HY, Dunbar JD, Zhang YX, Guo DおよびDonner DB. 1995 "Identification of a protein with homology to hsp90 that binds the type 1 tumour necrosis factor receptor", J. Biol. Chem., Vol. 270, pp. 3574-3581.
Supko JG, Hickman RL, Grever MRおよびMalspeis L. 1995 "Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent", Cancer Chemother. Pharmacol., Vol. 36, pp. 305-315.
Trost etal, 1998, J. Clin. Invest., Vol.101, pp.855.
Tytell MおよびHooper PL. 2001 "Heat shock proteins: new keys to the development of cytoprotective therapies", Emerging Therapeutic Targets, Vol. 5, pp. 267-287.
Waxman, Lloyd H. Inhibiting hepatitis C virus processing and replication. (Merck & Co., Inc., USA). PCT Int. Appl. (2002), WO 0207761
Whitesell L, Mimnaugh EG, De Costa B, Myers CEおよびNeckers LM. 1994 "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation", Proc. Natl. Acad. Sci. U S A., Vol. 91, pp. 8324-8328.
Young JC, Moarefi IおよびHartl FU. 2001 "HSP90: a specialized but essential protein-folding tool", J. Cell. Biol., Vol. 154, pp. 267-273.
Zhao JF, Nakano HおよびSharma S. 1995 "Suppression of RAS and MOS transformation by radicicol", Oncogene, Vol. 11, pp. 161-173.
Claims (8)
- 式(IE):
R9は-CH2NR10R11または-NR10R11 (ここで、-NR10R11は、モルホリニル、ピペリジニル、ピペラジニル、ピロリジニル、エチルアミノ、イソプロピルアミノ、ジエチルアミノ、シクロヘキシルアミノ、シクロペンチルアミノ、メトキシエチルアミノ、ピペリジン-4-イル、N-アセチルピペラジニル、N-メチルピペラジニル、メチルスルホニルアミノ、チオモルホリニル、チオモルホリニルジオキサイド、4-ヒドロキシエチルピペリジニルまたは4-ヒドロキシピペリジニルから選択される溶解補助基であり;そして
R8は、(C 1 〜C 6 )アルキル、(C 1 〜C 6 )アルコキシ、ヒドロキシ、ヒドロキシ(C 1 〜C 6 )アルキル、メルカプト、メルカプト(C 1 〜C 6 )アルキル、(C 1 〜C 6 )アルキルチオ、ハロ(フルオロ、ブロモおよびクロロを含む)、トリフルオロメチル、トリフルオロメトキシ、ニトロ、ニトリル(-CN)、オキソ、フェニル、-COOH、-COOR A 、-COR A 、-SO 2 R A 、-CONH 2 、-SO 2 NH 2 、-CONHR A 、-SO 2 NHR A 、-CONR A R B 、-SO 2 NR A R B 、-NH 2 、-NHR A 、-NR A R B 、-OCONH 2 、-OCONHR A 、-OCONR A R B 、-NHCOR A 、-NHCOOR A 、-NR B COOR A 、-NHSO 2 OR A 、-NR B SO 2 OH、-NR B SO 2 OR A 、-NHCONH 2 、-NR A CONH 2 、-NHCONHR B 、-NR A CONHR B 、-NHCONR A R B または-NR A CONR A R B (ここで、R A およびR B は独立して(C 1 〜C 6 )アルキル基である)から選択される任意の置換基を表す]
の化合物、またはその位置異性体式:
を有する化合物、またはそれらの塩、水和物もしくは溶媒和物。 - R 8 がエチル、イソプロピル、ブロモまたはクロロである、請求項1に記載の化合物。
- 化合物が:
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-エチルアミノメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-[4-(イソプロピルアミノ-メチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
4-(4-シクロヘキシルアミノメチル-フェニル)-5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-[4-[(2-メトキシ-エチルアミノ)-メチル]-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 イソプロピルアミド
5-(2,4-ジヒドロキシ-5-イソプロピル-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 イソプロピルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(2,4-ジヒドロキシ-5-イソブチル-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-tert-ブチル-2,4-ジヒドロキシ-フェニル)-4-(4-ジエチルアミノメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
3-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-5-カルボン酸 エチルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(4,6-ジヒドロキシ-2'-メチル-ビフェニル-3-イル)-イソオキサゾール-3-カルボン酸 エチルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(4,6-ジヒドロキシ-ビフェニル-3-イル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(4,6-ジヒドロキシ-ビフェニル-3-イル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-ピペリジン-1-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 イソプロピルアミド
4-(4-ジエチルアミノメチル-フェニル)-5-(5-エチル-2,4-ジヒドロキシ-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-エチル-2,4-ジヒドロキシ-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-エチル-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-ジエチルアミノメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-[4-(4-メチル-ピペラジン-1-イルメチル)-フェニル]-イソオキサゾール-3-カルボン酸 エチルアミド
5-(5-クロロ-2,4-ジヒドロキシ-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド
ならびにそれらの塩、水和物および溶媒和物から選択される、請求項1に記載の化合物。 - 5-(2,4-ジヒドロキシ-5-イソブチル-フェニル)-4-(4-モルホリン-4-イルメチル-フェニル)-イソオキサゾール-3-カルボン酸 エチルアミド、またはその塩、水和物もしくは溶媒和物である請求項1に記載の化合物。
- 請求項1〜4のいずれか一つに記載の化合物を医薬的に許容される担体と一緒に含む医薬組成物。
- 無菌の生理学的に許容される担体中の化合物が溶液または懸濁液の形態にある、請求項5に記載の医薬組成物。
- 無菌の生理的食塩水中の化合物が溶液または懸濁液の形態にある、請求項6に記載の医薬組成物。
- 請求項5〜7のいずれか一つに記載の癌の治療のための医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0303105.1 | 2003-02-11 | ||
GB0303105A GB0303105D0 (en) | 2003-02-11 | 2003-02-11 | Isoxazole compounds |
GBGB0306560.4A GB0306560D0 (en) | 2003-03-21 | 2003-03-21 | Isoxazole compounds |
GB0306560.4 | 2003-03-21 | ||
GB0313751A GB0313751D0 (en) | 2003-06-13 | 2003-06-13 | Isoxazole compounds |
GB0313751.0 | 2003-06-13 | ||
PCT/GB2004/000506 WO2004072051A1 (en) | 2003-02-11 | 2004-02-09 | Isoxazole compounds as inhibitors of heat shock proteins |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006517572A JP2006517572A (ja) | 2006-07-27 |
JP2006517572A5 JP2006517572A5 (ja) | 2007-05-10 |
JP4921162B2 true JP4921162B2 (ja) | 2012-04-25 |
Family
ID=32872455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006502254A Expired - Lifetime JP4921162B2 (ja) | 2003-02-11 | 2004-02-09 | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
Country Status (19)
Country | Link |
---|---|
US (6) | US7705027B2 (ja) |
EP (1) | EP1611112B1 (ja) |
JP (1) | JP4921162B2 (ja) |
KR (1) | KR101166749B1 (ja) |
CN (1) | CN1771235B (ja) |
AU (1) | AU2004210779B2 (ja) |
BR (1) | BRPI0407403B1 (ja) |
CA (1) | CA2515726C (ja) |
CY (1) | CY1113761T1 (ja) |
DK (1) | DK1611112T3 (ja) |
EA (1) | EA009919B1 (ja) |
ES (1) | ES2393483T3 (ja) |
HK (1) | HK1091831A1 (ja) |
MX (1) | MXPA05008335A (ja) |
NO (1) | NO335001B1 (ja) |
NZ (1) | NZ541479A (ja) |
PT (1) | PT1611112E (ja) |
SI (1) | SI1611112T1 (ja) |
WO (1) | WO2004072051A1 (ja) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
PT1611112E (pt) | 2003-02-11 | 2012-11-02 | Cancer Rec Tech Ltd | Compostos de isoxazole como inibidores de proteínas de choque térmico |
GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
EP1704856A4 (en) * | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
PL1748767T3 (pl) | 2004-05-28 | 2012-08-31 | Unigen Inc | 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
KR101313027B1 (ko) | 2004-06-23 | 2013-10-02 | 신타 파마슈티칼스 코프. | 암 치료용 비스(티오-히드라지드 아미드) 염 |
CA2581125C (en) | 2004-09-22 | 2013-04-23 | Nippon Kayaku Kabushiki Kaisha | Modified poly(ethylene oxide-amino acid) copolymer, micelle preparation, and anticancer agent containing the same |
EP1813270A4 (en) | 2004-11-09 | 2009-07-01 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITORS OF THE HSP90 FAMILY |
MX2007005940A (es) | 2004-11-18 | 2007-06-19 | Synta Pharmaceuticals Corp | Compuestos de triazol que modulan la actividad hsp90. |
DE102005007304A1 (de) * | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
AU2006214164B2 (en) | 2005-02-17 | 2010-12-09 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
FR2882361A1 (fr) * | 2005-02-22 | 2006-08-25 | Aventis Pharma Sa | Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation |
JP4956737B2 (ja) * | 2005-02-23 | 2012-06-20 | 国立大学法人名古屋大学 | 抗ポリグルタミン病剤 |
US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
CN1834095B (zh) * | 2005-03-18 | 2011-04-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
JP2008137894A (ja) * | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
EP1877379B1 (en) | 2005-04-13 | 2013-01-16 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
NZ562572A (en) | 2005-04-15 | 2011-01-28 | Synta Pharmaceuticals Corp | Combination cancer therapy with BIS (thiohydrazide) amide compounds |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
WO2006126751A1 (en) * | 2005-05-25 | 2006-11-30 | Korea Research Institute Of Bioscience And Biotechnology | New diaryl-isoxazole derivatives, and pharmaceutical compositions containing the same for the prevention and the treatment of cancers |
WO2007094819A2 (en) | 2005-08-18 | 2007-08-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
GB0603880D0 (en) * | 2006-02-27 | 2006-04-05 | Novartis Ag | Organic compounds |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
WO2007131034A1 (en) * | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
CN101448875A (zh) | 2006-05-18 | 2009-06-03 | 日本化药株式会社 | 鬼臼毒素类的高分子量结合体 |
WO2008024303A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
WO2008027445A2 (en) | 2006-08-31 | 2008-03-06 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
JP2010503674A (ja) * | 2006-09-14 | 2010-02-04 | シンタ ファーマシューティカルズ コーポレーション | 血管形成治療用化合物 |
CA2664852A1 (en) | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of resorcinol derivatives |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073804B1 (en) | 2006-10-12 | 2017-09-13 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
WO2008044027A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
WO2008056596A1 (en) | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
US7799954B2 (en) | 2006-11-17 | 2010-09-21 | Abraxis Bioscience, Llc | Dicarbonyl derivatives and methods of use |
KR20090122218A (ko) * | 2007-03-01 | 2009-11-26 | 노파르티스 아게 | 5-(2,4-디히드록시-5-이소프로필-페닐)-4-(4-모르폴린-4-일메틸-페닐)-이속사졸-3-카르복실산 에틸아미드의 산 부가염, 수화물 및 다형체, 및 이들 형태를 포함하는 제제 |
EP2183237A1 (en) | 2007-07-25 | 2010-05-12 | F. Hoffmann-Roche AG | Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
CN104072489B (zh) | 2007-08-27 | 2017-07-07 | 达特神经科学(开曼)有限公司 | 治疗用异噁唑化合物 |
WO2009026658A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Ppar agonists |
EP2206502B1 (en) | 2007-09-28 | 2018-09-12 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of steroid |
TW200922595A (en) * | 2007-10-12 | 2009-06-01 | Novartis Ag | Organic compounds |
US7932279B2 (en) | 2007-10-12 | 2011-04-26 | Arqule, Inc. | Substituted tetrazole compounds and uses thereof |
WO2009055917A1 (en) * | 2007-11-02 | 2009-05-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
EP2258397B1 (en) | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of physiologically active substance |
GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
LT5623B (lt) | 2008-04-30 | 2010-01-25 | Biotechnologijos Institutas, , | 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti |
EP2284209B1 (en) | 2008-05-08 | 2016-08-31 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
CN102098918A (zh) * | 2008-05-13 | 2011-06-15 | 帕纳德制药公司 | 用于治疗癌症和神经退行性疾病的生物活性化合物 |
TWI450898B (zh) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | 具有抗腫瘤活性之芳基異唑化合物 |
EP4046619A1 (en) | 2008-07-21 | 2022-08-24 | Unigen, Inc. | Series of skin-whitening (lightening) compounds |
EP2370103B1 (en) * | 2008-11-28 | 2016-03-23 | Novartis AG | Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab |
HUE031367T2 (en) * | 2008-11-28 | 2017-07-28 | Novartis Ag | A pharmaceutical combination comprising an Hsp 90 inhibitor and a mTOR inhibitor |
EP2421833B1 (en) | 2009-04-21 | 2015-01-14 | Nerviano Medical Sciences S.r.l. | Resorcinol derivatives as hsp90 inhibitors |
WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
JPWO2011040421A1 (ja) | 2009-09-29 | 2013-02-28 | 武田薬品工業株式会社 | スクリーニング方法 |
HUE026447T2 (en) | 2009-10-16 | 2016-05-30 | Novartis Ag | Pharmacodynamic tumor response biomarkers |
WO2011102660A2 (en) * | 2010-02-17 | 2011-08-25 | Ildong Pharm Co., Ltd. | A novel 5-membered heterocycle derivatives and manufacturing process thereof |
WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
CA2816997A1 (en) | 2010-11-17 | 2012-05-24 | Nippon Kayaku Kabushiki Kaisha | Novel polymer derivative of cytidine metabolic antagonist |
US8586799B2 (en) | 2011-03-24 | 2013-11-19 | Unigen, Inc. | Compounds and methods for preparation of diarylpropanes |
WO2013015661A2 (en) * | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
CN102351655A (zh) * | 2011-08-18 | 2012-02-15 | 杭州澳赛诺化工有限公司 | 一种4-异丙基间苯二酚的合成方法 |
KR101849142B1 (ko) | 2011-09-11 | 2018-04-16 | 니폰 가야꾸 가부시끼가이샤 | 블록 공중합체의 제조방법 |
KR20140078656A (ko) | 2011-10-14 | 2014-06-25 | 노파르티스 아게 | 증식성 질환의 치료를 위한 hsp90 억제제와 조합된 2-카르복스아미드 시클로아미노 우레아 유도체 |
CN103086994A (zh) * | 2011-10-31 | 2013-05-08 | 上海壹志医药科技有限公司 | 异噁唑衍生物的盐 |
CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
CA2890699A1 (en) | 2012-11-07 | 2014-05-15 | Novartis Ag | Combination therapy |
PL2917181T3 (pl) * | 2012-11-09 | 2020-08-24 | Mmv Medicines For Malaria Venture | Pochodne heteroarylowe i ich zastosowania |
WO2014074778A1 (en) | 2012-11-09 | 2014-05-15 | Jacobus Pharmaceutical Company, Inc. | Aryl derivatives and uses thereof |
CA2902699A1 (en) * | 2013-03-15 | 2014-09-18 | Novartis Ag | Biomarker |
AU2014302458A1 (en) * | 2013-06-26 | 2015-12-24 | Proteostasis Therapeutics, Inc. | Methods of modulating CFTR activity |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
WO2015196071A1 (en) * | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
RU2692782C2 (ru) * | 2014-10-01 | 2019-06-27 | Дайити Санкио Компани, Лимитед | Производное изоксазола в качестве ингибитора мутантной изоцитратдегидрогеназы 1 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
CN104725329B (zh) * | 2015-01-13 | 2017-01-18 | 陕西科技大学 | 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法 |
TWI688562B (zh) * | 2015-01-22 | 2020-03-21 | 大陸商正大天晴藥業集團股份有限公司 | 作為hsp90抑制劑的間苯二酚類衍生物及其製備方法 |
KR20170129802A (ko) | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
CN106349180B (zh) * | 2015-07-14 | 2020-05-19 | 上海翰森生物医药科技有限公司 | 4,5-二苯基异噁唑衍生物及其制备方法和应用 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
CN107540624B (zh) * | 2016-06-29 | 2020-06-16 | 广州市恒诺康医药科技有限公司 | 热休克蛋白抑制剂及其制备方法和应用 |
CN106146466A (zh) * | 2016-06-30 | 2016-11-23 | 珠海赛隆药业股份有限公司(长沙)医药研发中心 | 富马酸沃诺拉赞中间体、其制备方法和制备富马酸沃诺拉赞的方法 |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018014858A1 (zh) * | 2016-07-21 | 2018-01-25 | 正大天晴药业集团股份有限公司 | 间苯二酚类衍生物的结晶、盐及其制备方法 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CN111217762B (zh) * | 2018-11-23 | 2021-08-20 | 华中师范大学 | 多卤代5-(2-羟基苯基)异噁唑类化合物及其制备方法和应用 |
WO2020231979A1 (en) * | 2019-05-13 | 2020-11-19 | The Trustees Of Princeton University | Small molecule inhibitors of viral replication |
CN110283080A (zh) * | 2019-07-05 | 2019-09-27 | 山西大学 | 一种含氟的二苯甲酮衍生物及其制备方法和应用 |
WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
KR102676631B1 (ko) * | 2020-10-07 | 2024-06-19 | 광주과학기술원 | 과민성 방광의 예방 또는 치료용 약학적 조성물 |
CN115160250B (zh) * | 2021-04-02 | 2024-06-04 | 沈阳药科大学 | 4,6-联苯二酚类衍生物及其用途 |
US11324737B1 (en) * | 2021-05-25 | 2022-05-10 | Louis Habash | Modulating expression level of a gene encoding a heat shock protein by treating a human subject with a nitroxide |
US11729925B2 (en) | 2021-06-15 | 2023-08-15 | Erico International Corporation | Mounting bracket with angled mounting openings for electrical boxes |
CN114751870B (zh) * | 2022-02-28 | 2023-10-20 | 贵州医科大学 | 一种2-(异噁唑-5-基)苯基-3,4-二羟基苯甲酸酯及其衍生物及合成方法和应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03130270A (ja) * | 1989-09-22 | 1991-06-04 | Basf Ag | 新規カルボン酸アミド及び除草剤 |
WO1994024095A1 (en) * | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
WO2001012621A1 (en) * | 1999-08-13 | 2001-02-22 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
JP2001503395A (ja) * | 1996-10-15 | 2001-03-13 | ジー.ディー.サール アンド カンパニー | 腫瘍新生の処置および予防にシクロオキシゲナーゼ―2阻害剤を使用する方法 |
JP2001506271A (ja) * | 1996-12-23 | 2001-05-15 | デュポン ファーマシューティカルズ カンパニー | Xa因子阻害剤としての酸素またはイオウを含む複素環式芳香族化合物 |
WO2001047935A2 (en) * | 1999-12-22 | 2001-07-05 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
JP2002522425A (ja) * | 1998-08-07 | 2002-07-23 | カイロン コーポレイション | エストロゲンレセプターモジュレーターとしての置換イソオキサゾール |
JP2002524463A (ja) * | 1998-09-09 | 2002-08-06 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−1,6−ビスホスファターゼの新規な芳香族インヒビター |
JP2002363079A (ja) * | 2001-05-31 | 2002-12-18 | National Cancer Center-Japan | モフェゾラクを有効成分とする、消化管ポリープおよび/または消化管がんの予防または治療のための薬剤 |
US20030032657A1 (en) * | 2001-04-20 | 2003-02-13 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019604A1 (fr) * | 1991-05-01 | 1992-11-12 | Taiho Pharmaceutical Co., Ltd. | Nouveau derive d'isoxazole et sel de ce derive |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
AU2002356301A1 (en) * | 2001-12-21 | 2003-07-15 | Cancer Research Technology Ltd. | 3,4-diarylpyrazoles and their use in the therapy of cancer |
PT1611112E (pt) * | 2003-02-11 | 2012-11-02 | Cancer Rec Tech Ltd | Compostos de isoxazole como inibidores de proteínas de choque térmico |
US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
-
2004
- 2004-02-09 PT PT04709273T patent/PT1611112E/pt unknown
- 2004-02-09 KR KR1020057014738A patent/KR101166749B1/ko active IP Right Grant
- 2004-02-09 ES ES04709273T patent/ES2393483T3/es not_active Expired - Lifetime
- 2004-02-09 EA EA200501272A patent/EA009919B1/ru active IP Right Revival
- 2004-02-09 JP JP2006502254A patent/JP4921162B2/ja not_active Expired - Lifetime
- 2004-02-09 CA CA2515726A patent/CA2515726C/en not_active Expired - Lifetime
- 2004-02-09 CN CN2004800093392A patent/CN1771235B/zh not_active Expired - Lifetime
- 2004-02-09 AU AU2004210779A patent/AU2004210779B2/en not_active Expired
- 2004-02-09 DK DK04709273.9T patent/DK1611112T3/da active
- 2004-02-09 US US10/544,443 patent/US7705027B2/en not_active Expired - Lifetime
- 2004-02-09 EP EP04709273A patent/EP1611112B1/en not_active Expired - Lifetime
- 2004-02-09 NZ NZ541479A patent/NZ541479A/en not_active IP Right Cessation
- 2004-02-09 MX MXPA05008335A patent/MXPA05008335A/es active IP Right Grant
- 2004-02-09 WO PCT/GB2004/000506 patent/WO2004072051A1/en active Search and Examination
- 2004-02-09 BR BRPI0407403-3A patent/BRPI0407403B1/pt active IP Right Grant
- 2004-02-09 SI SI200431954T patent/SI1611112T1/sl unknown
-
2005
- 2005-09-09 NO NO20054195A patent/NO335001B1/no unknown
-
2006
- 2006-11-10 HK HK06112447.8A patent/HK1091831A1/xx not_active IP Right Cessation
-
2010
- 2010-02-19 US US12/708,686 patent/US8507480B2/en active Active
-
2012
- 2012-06-18 US US13/525,409 patent/US8450310B2/en not_active Expired - Lifetime
- 2012-11-09 CY CY20121101068T patent/CY1113761T1/el unknown
-
2013
- 2013-06-27 US US13/929,098 patent/US9718793B2/en not_active Expired - Lifetime
-
2017
- 2017-06-23 US US15/631,059 patent/US10413550B2/en not_active Expired - Lifetime
-
2019
- 2019-07-31 US US16/528,278 patent/US11234987B2/en not_active Expired - Lifetime
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03130270A (ja) * | 1989-09-22 | 1991-06-04 | Basf Ag | 新規カルボン酸アミド及び除草剤 |
WO1994024095A1 (en) * | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
JP2001503395A (ja) * | 1996-10-15 | 2001-03-13 | ジー.ディー.サール アンド カンパニー | 腫瘍新生の処置および予防にシクロオキシゲナーゼ―2阻害剤を使用する方法 |
JP2001506271A (ja) * | 1996-12-23 | 2001-05-15 | デュポン ファーマシューティカルズ カンパニー | Xa因子阻害剤としての酸素またはイオウを含む複素環式芳香族化合物 |
JP2002522425A (ja) * | 1998-08-07 | 2002-07-23 | カイロン コーポレイション | エストロゲンレセプターモジュレーターとしての置換イソオキサゾール |
JP2002524463A (ja) * | 1998-09-09 | 2002-08-06 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−1,6−ビスホスファターゼの新規な芳香族インヒビター |
JP2003515523A (ja) * | 1998-12-24 | 2003-05-07 | メタベイシス・セラピューティクス・インコーポレーテッド | 糖尿病治療のためのfbpアーゼ阻害物質とインスリンセンシタイザの組み合わせ |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
WO2001012621A1 (en) * | 1999-08-13 | 2001-02-22 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
WO2001047935A2 (en) * | 1999-12-22 | 2001-07-05 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
JP2003519154A (ja) * | 1999-12-22 | 2003-06-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なビスアミダートホスホネートプロドラッグ |
US20030032657A1 (en) * | 2001-04-20 | 2003-02-13 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
JP2002363079A (ja) * | 2001-05-31 | 2002-12-18 | National Cancer Center-Japan | モフェゾラクを有効成分とする、消化管ポリープおよび/または消化管がんの予防または治療のための薬剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4921162B2 (ja) | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 | |
JP4528131B2 (ja) | ピラゾール化合物 | |
JP4575779B2 (ja) | 癌治療用のhsp90阻害剤としての3−(2−ヒドロキシ−フェニル)−1h−ピラゾール−4−カルボン酸アミド誘導体 | |
JP4783731B2 (ja) | ピリミドチオフェン化合物 | |
JP4891904B2 (ja) | ピリミドチオフェン化合物 | |
US8796320B2 (en) | 1,3,4-Oxadiazole-2-carboxamide compound | |
CN100455586C (zh) | 嘧啶并噻吩化合物 | |
WO2006090094A1 (en) | Pyrimidothiophene compounds for use as hsp90 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051013 |
|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20051007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100921 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110926 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120124 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4921162 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150210 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |